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ABSTRACT 
THE ROLE OF SLC7A11 IN CONTROLLING EXTRACELLULAR AND 
INTRACELLULAR REDOX ENVIRONMENTS OF LUNG FIBROBLASTS – 
POTENTIAL TARGETS FOR INTERVENTION IN AGING AND IDIOPATHIC 
PULMONARY FIBROSIS 
Yuxuan Zheng 
April 9, 2020  
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by 
extracellular matrix deposition by fibroblasts. Aging and oxidative stress 
increase the susceptibility to IPF. Redox couples, cysteine/cystine (Cys/CySS) 
and glutathione/glutathione disulfide (GSH/GSSG), and their redox potentials 
(Eh) quantify oxidative stress. Fibroblasts from old mice maintain more oxidized 
extracellular Eh(Cys/CySS) than young mice. Microarray shows down-
regulation of Slc7a11 potentially mediates this age-related oxidation. Slc7a11 
is the key component of system Xc-, an antiporter that imports CySS and 
exports glutamate. The first aim of this dissertation is to investigate the 
mechanistic link between Slc7a11 expression and extracellular Eh(Cys/CySS). 
The second aim is to evaluate the effects of aging on the redox states of 
intracellular proteins and whether Slc7a11 contributes to the age-dependent 
effects. The last aim is to compare SLC7A11 expression, extracellular
vii 
Eh(Cys/CySS) and intracellular Eh(GSH/GSSG) between human lung 
fibroblasts from IPF and non-IPF donors and to explore their association with 
pro-fibrotic gene expression.  
Slc7a11 expression was manipulated by pharmacological and genetic 
methods. Reduced and oxidized forms of Cys residues were labelled by 
Iodoacetyl Tandem Mass Tags. The ratio of oxidized/reduced forms (i.e., redox 
state) of a Cys residue was determined by multiplexed tandem mass 
spectrometry. 
Eh(Cys/CySS) and Eh(GSH/GSSG) were more oxidized in conditioned 
media of old fibroblasts. Up-regulation of Slc7a11 reduced extracellular 
Eh(Cys/CySS) for old fibroblasts. Inhibition of GSH synthesis had no effect on 
the ability of cells to restore their extracellular Eh(Cys/CySS). Redox states of 
151 proteins changed with aging. Slc7a11 over-expression restored redox 
states of 104 proteins. Ingenuity Pathway Analysis showed these 104 proteins 
were involved in pathways of protein translation initiation, ubiquitin-
proteasome-mediated degradation and integrin-cytoskeleton-associated 
signaling. Slc7a11 expression was lower in IPF fibroblasts. Extracellular 
Eh(Cys/CySS) was more oxidized and expression of pro-fibrotic genes was 
higher in IPF fibroblasts. 
In conclusion, Slc7a11 is the key regulator of extracellular Eh(Cys/CySS). 
Its effects are independent of GSH synthesis. Aging results in changes of redox 
states of proteins involved in protein turnover and cytoskeleton dynamics. Up-
viii 
regulating Slc7a11 restores changes of protein redox states due to aging. 
Decreased SLC7A11 might represent a susceptibility factor for developing 
tissue disrepair and fibrosis in IPF.
ix 
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CHAPTER I 
 
INTRODUCTION 
 
1.1 Overview of idiopathic pulmonary fibrosis (IPF) 
Idiopathic pulmonary fibrosis (IPF) is characterized by scarring of the lung 
without known causes. Normally, the connective tissues between alveoli are 
very thin so that oxygen can diffuse effectively. However, IPF is characterized 
by irreversible destruction of alveoli and remodeling of lung with excessive 
synthesis and deposition of extracellular matrix (ECM) in the interstitial spaces 
(1). As the interstitium becomes thicken, the function of the lung for gas 
exchange gradually declines. According to the American Thoracic Society (ATS) 
guideline, IPF is defined as “a specific form of chronic, progressive fibrosing 
interstitial pneumonia of unknown cause, occurring primarily in older adults, 
limited to the lungs, and associated with histopathologic and/or radiologic 
pattern of usual interstitial pneumonia (UIP)” (2). 
Generally, the pathological pattern of IPF is UIP. Although not 
pathognomonic, pathological UIP increases the confidence of IPF diagnosis if 
radiological UIP pattern is suspected but not well established after patient 
history is thoroughly reviewed and potential causes are excluded (3). Fibrosis 
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in IPF is primarily located at the periphery of the lower regions of both lungs. 
Two distinctive characteristics of UIP are honeycombing and fibroblast foci (4). 
Honeycombing refers to the enlarged air cysts lined with bronchiolar-type 
epithelium and filled with mucin and inflammatory cells, while fibroblast foci are 
aggregates of fibroblasts and myofibroblasts that are actively producing matrix 
proteins (5). 
The increasing prevalence and fatality of IPF require people’s awareness. 
There are over 180,000 IPF patients in the United States (6). According to an 
epidemiological study among Medicare beneficiaries over 65 years of age, the 
prevalence of IPF increased dramatically from 202.2 cases per 100,000 person-
years in 2001 to 494.5 cases per 100,000 person-years in 2011 (7). 
Furthermore, IPF is a disease of aging. It predominantly develops in people 
over 55 years old and its incidence increases with aging (8, 9). The median age 
at diagnosis is 66 years old (10). Sex and ethnicity also affect susceptibility to 
IPF. The incidence in males is higher than that of females (9). Caucasians and 
Hispanics are more susceptible than African-Americans and Asians (7). 
Mortality also increases with aging and is higher in Caucasians (7, 11). The 
survival of IPF is worse than most cancers. The median survival time is 2 to 3 
years (10, 12). Its five-year survival is only higher than pancreatic cancer and 
lung cancer (13). 
The diagnosis of IPF is complex and dependent on a multidisciplinary 
approach. Patients usually present with shortness of breath, dry cough and 
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fatigue, which are chronic but non-specific. Typically, bibasilar inspiratory 
crackles are present in physical exam. Basic information and history of the 
patient, including age, sex, smoking status, family history and environmental 
exposures need to be carefully evaluated to exclude potential causes. High-
resolution computed tomography (HRCT) is usually required. Based on 
whether the pattern of HRCT is UIP, how confident the UIP pattern is 
established and whether surgical lung biopsy is practical, multidisciplinary 
discussion is suggested to determine diagnosis and further management of the 
patient (3, 14). 
There is no cure for IPF, but several treatments are available to increase 
patients’ wellbeing or slow down IPF progression. Pulmonary rehabilitation, 
including exercise, emotional support and education, aims to improve overall 
physical health and quality of life (15, 16). Supplemental oxygen becomes 
necessary during the IPF course at some point (17). Pirfenidone and nintedanib 
are the two US FDA approved anti-fibrotic drugs. Their major effect is to slow 
down deterioration of patients’ lung function (18, 19). Side effects include 
nausea and anorexia for pirfenidone and diarrhea for nintedanib. Both drugs 
affect cytochrome P450. Therefore, usage of other drugs and liver function 
should be monitored. Though lung transplantation is another option, the 
posttransplant survival remains low (20). 
Pathogenesis of IPF is multifaceted. Current paradigm focuses on aberrant 
wound healing and lung remodeling affected by various factors, including 
4 
genetics, aging, environmental exposures, oxidative stress, interplay between 
epithelial cells, inflammatory cells and fibroblasts via cytokines, and interaction 
between cells and the environments (matrix or redox) they reside in. 
Gene polymorphism and mutation determines susceptibility to IPF. A single 
nucleotide polymorphism guanine to thymine in MUC5B promoter has been 
confirmed to increase susceptibility (21). Patients with familial pulmonary 
fibrosis present symptoms earlier than sporadic IPF (22). Genes encoding 
surfactant, telomerase and innate immune-related toll interacting protein are 
also associated with IPF (23-26). 
Aging is the most important host factor for increasing IPF susceptibility. 
Aging is characterized by impaired physiological function and degenerated 
biological structure (27). Age-related deficiencies, such as oxidative stress, 
genetic instability and epigenetic change are all identified in IPF epithelial cells 
or fibroblasts, suggesting the processes of aging overlap with and promote 
development of IPF (28). Lung fibroblasts isolated from IPF patients exhibit 
cellular senescence compared to those from their age-matched controls (29). 
Bleomycin induces more severe lung fibrosis in old mice than young mice via 
activating pro-fibrotic TGF-β1/Smad signaling pathway (30). 
Recurrent environmental exposures induce repetitive damage that 
contribute to IPF development. Cigarette smoke, farming, livestock, dust of 
wood, metal, stone, sand and silica all increase IPF risk (31). Among them, 
cigarette smoke has the highest public health relevance because of the large 
5 
smoking population (32). Other proposed risk factors for recurrent microinjuries 
include viral infection, gastroesophageal reflux, change of lung microbiome, 
diabetes mellitus and obstructive sleep apnea (33). Those risk factors are 
mostly identified by retrospective case-control studies. Therefore, causal 
relationships cannot be established. 
Redox homeostasis is disrupted in IPF and oxidative stress has been 
implicated in IPF. The lungs are exposed to oxygen directly and sensitive to 
oxidative stress. Multiple biomarkers of oxidative stress, including protein 
carbonyls, 8-isoprostane and hydroperoxide, are increased (34). Oxidative 
stress also induces DNA damage, ECM fragmentation and pro-fibrotic cytokine 
activation, all of which promote aberrant wound healing and may increase the 
susceptibility to develop IPF (34). 
Injured epithelial cells are considered initiators of IPF. In the alveoli, most 
epithelial cells are type I alveolar epithelial cells (AECs). They maintain the 
shape of alveoli and allow for gas exchange. Damage of type I AECs signals 
the progenitor type II AECs to regenerate type I AECs to restore normal lung 
structure and function. However, during IPF development, repetitive 
microinjuries result in exhaustion of type II AECs (35). Epithelial reprogramming 
occurs and is accompanied by change of epithelial morphology (36). Re-
epithelialization is dysregulated, resulting in pathological honeycombing (37). 
Embryonic development pathways, such as Wnt and Sonic hedgehog 
pathways, are also reactivated (38, 39). Epithelial cells secret chemokines to 
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recruit fibroblasts, growth factors and pro-fibrotic cytokines to induce 
proliferation, migration and activation of fibroblasts (37, 40). They also secret 
procoagulants to increase the risk of thromboembolism (41). Unfolded protein 
response and endoplasmic reticulum stress induce epithelial apoptosis and 
epithelial-mesenchymal transition, which play critical roles in IPF pathogenesis 
(42, 43).  
The role of inflammatory cells in IPF is controversial. There is only mild 
inflammation in IPF, and anti-inflammatory therapies are not effective (44). 
Whether inflammatory cells are pro- or anti-fibrotic depends on context and 
mediators they secret (45). 
Fibroblasts are the effector cells. Fibroblasts isolated from lungs of IPF 
patients have slower growth rate, flattened shape and decreased telomere 
length, indicating replicative senescence (29, 46). They are also activated to 
differentiate into more contractile, invasive and apoptosis-resistant 
myofibroblasts (47). Myofibroblasts not only originate from local resident 
fibroblasts, but also from other resources including circulating bone marrow 
derived fibrocytes, pericytes and epithelial- or endothelial-mesenchymal 
transition (48). Fibroblasts and myofibroblasts form fibrotic foci, where they 
produce exuberant and aberrant ECM proteins and determine the fibrotic 
phenotype of IPF (49, 50). 
The behavior of fibroblasts is dependent on the interaction between 
fibroblasts and their surrounding environment. Serum deprivation-induced 
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fibroblast apoptosis is blocked by TGF-β (51). Furthermore, adherent 
fibroblasts express α-smooth muscle actin (α-SMA) in response to TGF, while 
suspended fibroblasts lose such response (52). 
ECM is one important factor that determines fibroblast phenotype. The 
function of matrix is to maintain structural framework and elasticity of the lung. 
Fibroblasts, which produce ECM, are prone to cluster in areas with higher 
matrix stiffness, resulting in aggravation of IPF via a positive feedback loop (53). 
Fibroblasts display elongated and dendritic shape, increased proliferation and 
migration, decreased apoptosis, increased collagen expression and decreased 
expression of proteolysis-associated genes on substrate with higher stiffness 
(53).  
Comparable to the matrix environment, the redox environment is another 
important factor that changes fibroblast behavior. This will be discussed in detail 
in the following sections. 
No ideal animal models are available for simulating human IPF. Current 
animal models are based on injury-induced lung fibrosis without idiopathic or 
spontaneous nature. Different models have their own advantages and 
disadvantages (54). The most commonly used model is intratracheal 
bleomycin-induced lung fibrosis in mice (55). Bleomycin causes breaks of DNA 
strands and generation of free radicals specifically in the lung due to lack of its 
hydrolase. The major limitations of this model are that bleomycin induces 
considerable inflammation and the fibrosis is self-limited, both of which are not 
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consistent with IPF (56). This model can be divided into 3 stages including pro-
inflammatory phase, transitional phase and fibrotic phase (57). Other chemicals 
to induce lung fibrosis include silica, radiation, asbestos, paraquat and 
fluorescent isothiocyanate (58). 
1.2 Oxidative stress and its role in IPF 
Oxidative stress is classically defined as “an imbalance between pro-
oxidants and anti-oxidants in favor of the former” (59). Although there are some 
discrepancies, a plethora of studies have shown oxidative stress is increased 
in IPF and contributes to its pathogenesis (34, 60). 
Generally, pro-oxidants are increased. Compared to clinical samples from 
healthy donors, different kinds of reactive oxygen species (ROS) and oxidation 
products of lipids, proteins and DNA are increased in one or more IPF patients-
derived samples, including bronchoalveolar lavage (BAL), epithelial lining fluid 
(ELF), exhaled breath condensate (EBC), plasma, serum, urine, sputum, 
breath, specific type of lung cells and whole lung tissue. Superoxide anion (O2-) 
is increased in inflammatory cells from BAL (61). Hydrogen peroxide (H2O2) is 
increased in BAL, EBC and serum (61-64). 8-isoprostane is increased in BAL, 
EBC, plasma and serum (65-68). Carbonyls are increased in BAL (69, 70). 
Nitrotyrosine is increased in EBC, epithelial cells and inflammatory cells (66, 
71). Ethane is increased in breath (72). 8-hydroxy-deoxyguanosine (8-OHdG) 
is increased in epithelial cells (73). Some studies stratify subjects into smokers 
and non-smokers. Malondialdehyde (MDA) is increased in plasma of non-
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smokers with IPF compared to healthy non-smokers (74). 
On the other hand, non-enzymatic and enzymatic anti-oxidants are mostly 
decreased in IPF samples. 
Concentrations of reduced glutathione (GSH) and its oxidized form, 
glutathione disulfide (GSSG) are the most commonly measured non-enzymatic 
small molecular anti-oxidants. GSH is decreased in plasma (75). GSSG is 
increased in BAL and whole blood (76, 77). Total GSH (GSH + 2GSSG) is 
decreased in ELF, sputum and whole blood (77-80). The ratio of GSH to GSSG 
is decreased in whole blood (77). When smoking status is considered, GSH is 
decreased in BAL from non-smoking IPF patients than non-smoking health 
controls (74). It’s obvious that the balance of GSH/GSSG redox couple is 
disrupted in IPF. GSH is a tripeptide synthesized from cysteine, glutamate and 
glycine. In IPF lung tissue, these three amino acids are increased while GSH 
synthesis enzymes, including glutamate-cysteine ligase (GCL) and glutathione 
synthetase (GSS), are decreased (81). Trolox equivalent anti-oxidant capacity 
(TEAC), a measurement of total anti-oxidant capacity, decreased in both BAL 
and plasma from IPF patients in non-smoking subjects (74). Surprisingly, 
vitamins A, C, E and uric acid, which are generally considered anti-oxidants, 
are increased in BAL from IPF patients (76). 
Expression or activity of multiple anti-oxidant enzymes are changed in IPF, 
further disrupting redox homeostasis. Catalase (CAT) metabolizes H2O2 to 
water (H2O) and oxygen (O2). Both CAT expression and activity are decreased 
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in IPF lung tissue (82). Glutathione peroxidase (GPX) reduces H2O2 using GSH. 
GPX3 is up-regulated in IPF lung tissue (83). Superoxide dismutase (SOD) 
transforms O2- to H2O2 and O2. SOD3 is decreased in fibrotic areas of the IPF 
lung tissue compared to non-fibrotic areas (84). However, SOD1 is increased 
in the serum of IPF patients (85). Glutaredoxin (GRX) uses GSH to reduce 
protein S-glutathionylation (deglutathionylation). GRX expression and activity 
are decreased in IPF lung tissue (86). Thioredoxin (TRX) reduces intra- or inter-
molecular disulfide formed from two protein cysteine residues. TRX reductase 
regenerates reduced TRX using electrons from reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) (87). Immunochemistry staining shows 
neither TRX nor TRX reductase is expressed in normal alveolar epithelial cells 
(88). However, both TRX and TRX reductase are increased in metaplastic 
alveolar epithelial cells in IPF (88). Peroxiredoxin (PRX) metabolizes organic 
hydroperoxide (ROOH) and H2O2 to H2O or alcohol (ROH). Overall PRXII is 
decreased in IPF lung tissue (89). However, PRXII expression is increased in 
hyperplastic epithelium but decreased in fibroblasts foci (89). Sulfiredoxin (SRX) 
reduces cysteine sulfinic acid to sulfenic acid. SRX1 is increased in IPF lung 
tissue (90). Those cysteine-reducing enzyme systems are interconnected. TRX 
and GRX systems can both reduce cysteine disulfide or sulfenic acid back to 
thiols, regenerating functional PRX (91). SRX can also activate PRX via 
reducing cysteine sulfinic acid and use GSH to catalyze deglutathionylation, as 
with GRX (92, 93). Even they share similar functions and their substrates 
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overlap, these reducing systems are not entirely replaceable with each other 
since their reducing mechanisms are different and their substrate specificity 
remains incompletely understood (94).  
Although many anti-oxidants are decreased, the fact that some of these 
anti-oxidants are still increased and that expression of the anti-oxidant enzymes 
are cell type-specific and location-specific in IPF lungs suggest that redox 
disturbance in IPF is not simply due to a decrease in anti-oxidants, and that 
intricate redox-related regulatory mechanisms exist. Systems controlling 
intracellular and extracellular redox environments might be functionally 
connected with each other but regulated independently. And those systems 
could be differentially impaired during IPF pathogenesis. 
Why oxidative stress is increased and how redox imbalance promotes lung 
disrepair and fibrosis are incompletely elucidated. 
NADPH oxidases (NOXs) and mitochondria are the two major sources of 
ROS. Studies based on animal models of lung fibrosis have shown activity of 
different isoforms of NOXs are increased, resulting in increased production of 
ROS (95). Among them, NOX4 is the only isoform that has been confirmed to 
be upregulated in fibroblasts and smooth muscle cells from IPF lungs (96, 97). 
Dysfunctional mitochondria are another source of excessive ROS (98). O2 is 
partially reduced by electrons leaked from electron transport chain (99). 
Furthermore, there is an interplay between mitochondria and NOXs, which 
further aggregates ROS production (60). 
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Generally, increased oxidative stress induces epithelial apoptosis, 
promotes differentiation of fibroblasts into myofibroblasts to secret more 
extracellular matrix proteins, recruit inflammatory cells and disrupt the balance 
between pro- and anti-fibrotic cytokines. Oxidative stress also results in 
chemical modifications of lung matrix proteins, changing not only the structure 
and function of specific proteins, but also the biomechanics that might affect the 
interaction between fibroblasts and matrices. 
There is a vicious cycle between redox imbalance and TGF-β signaling 
(100). TGF-β is the major pro-fibrotic cytokine. It is present extracellularly in the 
inactive form consisting of dimeric TGF-β, latency-associated protein (LAP) and 
latent TGF-β binding protein (LTBP). ROS can activate TGF-β via modifying 
and dissociating LAP directly or indirectly via matrix metallopeptidase (MMP) 
mediated LAP cleavage (101, 102). ROS can also induce TGF-β expression 
(103, 104). On the other hand, TGF-β promotes redox imbalance. NOX4 is up-
regulated by TGF-β in fibroblasts from control and IPF patients (105). 
Mitochondria-derived ROS induced by TGF-β results in mitochondrial DNA 
damage and dysfunction in fibroblasts, promoting maladaptation and lung 
fibrosis (106). TGF-β also decreases GSH synthesis via inhibiting both catalytic 
and modifier subunits of glutamate-cysteine ligase (GCLC and GCLM) in 
mouse lung (107). In terms of anti-oxidant enzymes, GRX1 is down-regulated 
by TGF-β in A549 cells, an alveolar epithelial cell line derived from lung 
adenocarcinoma, and expressions of SOD2 and CAT are suppressed by TGF-
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β in airway smooth muscle cells (108, 109). 
Many pro-fibrotic effects on fibroblasts are dependent on ROS. Elimination 
of NOX4-produced ROS by N-acetylcysteine (NAC) or inhibition of NOX4 
blocks the effects of TGF-β to induce collagen expression and myofibroblast 
differentiation of fibroblasts (105). Serum-induced proliferation and invasion of 
IPF fibroblasts are blocked by NAC or NOX4 knockdown (110). Even without 
treatments, silencing NOX4 results in decreased basal expression of pro-
collagen, fibronectin and α-SMA in IPF fibroblasts (110). ROS over-production 
due to mitochondrial dysfunction contributes to IPF fibroblast senescence (111-
113). Anti-oxidants targeting mitochondria attenuate induction of α-SMA and 
NOX4 expression by TGF-β in IPF fibroblasts (114). Exogenous H2O2 increases 
α-SMA expression in a dose- and time-dependent manner in control lung 
fibroblasts while NAC reduces expressions of α-SMA and type-I collagen in 
early passages of IPF fibroblasts (115).  
ROS also mediates pro-fibrotic effects on other cell types and modifies 
matrix proteins. Anti-oxidants abrogates the effects of exogenous H2O2 to 
induce epithelial-to-mesenchymal transition (EMT) for A549 cells (116). SOD1-
mediated production of H2O2 polarizes macrophages to the M2 phenotype, 
promoting lung remodeling and fibrosis (117). H2O2 secreted by IPF fibroblasts 
induces small airway epithelial cell death (118). Exogenous H2O2 inhibits wound 
healing in a concentration-dependent manner via inducing apoptosis and 
suppressing migration of alveolar epithelial cells (119). Bleomycin-generated 
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ROS induces endothelial stress and differentiation of pericytes into 
myofibroblasts (120). ROS contributes to matrix dysregulation in IPF (121). 
Hyaluronic acid, which is increased in BAL from IPF patients, is prone to H2O2-
induced degradation (122, 123). Syndecan-1 is increased in both BAL and lung 
tissue from IPF patients (124). Its shedding and function as neutrophil 
chemoattractant are inhibited by SOD1 (124). 
Previous clinical trials targeting oxidative stress were unsuccessful. 
Compared to placebo, NAC monotherapy did not benefit IPF patients in terms 
of slowing down lung function deterioration or decreasing mortality (125). 
Surprisingly, NAC triple-therapy with prednisone and azathioprine increased 
the rate of death and hospitalization, and the study was terminated after interim 
analysis (44). The failure of those studies indicates providing exogenous anti-
oxidants to decrease overall oxidative stress might not be the way to treat IPF 
since many oxidants have physiological roles and giving anti-oxidants 
indiscriminately may disrupt those normal biological functions. However, NAC 
monotherapy was related to a significant decrease of risk of death and disease 
progression in patients with a TT genotype of the TOLLIP gene that plays 
important roles in lung host defense (26). The genotype-stratified effect further 
reveals the complexity of the redox regulation in IPF. Moreover, considering IPF 
pathogenesis is multifactorial, and pro-fibrotic pathways overlap and 
compensate for each other, interventions with pleiotropic effects might have a 
better chance of being effective than highly specific drugs that target a single 
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molecule or pathway (126). The ineffectiveness of overall anti-oxidants and 
highly selective drugs in general IPF patients facilitates us to think whether 
there will be other methods to intervene redox imbalance in a neither too 
general nor too specific manner. My proposed intervention against oxidative 
stress is manipulating redox couples and their redox potentials to restore redox 
homeostasis. 
1.3 Redox couples and their roles in lung fibrosis 
Redox couples provide a new aspect of studying oxidative stress. 
Traditional definition of oxidative stress emphasizes the overall imbalance 
between pro-oxidants and anti-oxidants. However, the sensitivity to oxidants 
and the response to anti-oxidants of different systems are not the same (127). 
Furthermore, traditional definition neglects the signaling role of redox 
modification and normal biological functions of specific redox molecules. 
Modern concept of oxidative stress adds the results of the redox imbalance, 
which are disruption of redox signaling and damage to biological molecules 
(128). Compared to ROS, redox couples have the advantage of being easier to 
measure and constituting a hierarchical regulatory network themselves (127). 
They can buffer oxidative stress and transduce signals via regulating redox 
environment or by affecting protein functions through oxidation and reduction 
of cysteine thiols (129, 130). 
Based on concentrations, cysteine/cystine (Cys/CySS) is the major 
extracellular redox couple while GSH/GSSG is the major intracellular redox 
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couple (131). There are several other intracellular redox couples as well, such 
as reduced/oxidized Trx and NADPH/NADP+ (132). Redox potential (Eh) is used 
to quantitatively describe the reducing ability of a redox couple to buffer 
oxidative stress and is calculated from the Nernst equation. Those redox 
couples are not in equilibrium with each other, which is another evidence of 
inadequacy of traditional balance definition of oxidative stress (131). In fact, 
even for a particular redox couple, its redox potential differs significantly in 
subcellular compartments (133). Normal human plasma GSH/GSSG redox 
potential (Eh(GSH/GSSG)) and plasma Cys/CySS redox couple (Eh(Cys/CySS)) 
are around -140 mV and -80 mV, respectively (134). Cytoplasmic 
Eh(GSH/GSSG) varies between -220 mV and -260 mV while cytoplasmic 
Eh(Cys/CySS) is close to -160 mV (133). Mitochondrial Eh(GSH/GSSG) and 
nuclear Eh(GSH/GSSG) are more reducing than cytoplasmic Eh(GSH/GSSG) 
(135). 
Though components of each redox couple are in dynamic status to maintain 
relatively stable redox potential, many factors can affect the set-point value of 
redox potential. Human plasma Eh(GSH/GSSG) and Eh(Cys/CySS) become 
progressively oxidized with aging (136, 137). They are also more oxidized in 
smokers compared to non-smokers (138). Plasma Eh(GSH/GSSG) becomes 
oxidized over time with chemotherapy (139). Other risk factors related with 
oxidation of plasma Eh(GSH/GSSG) or Eh(Cys/CySS) include high serum 
cholesterol level, low sulfur amino acid diet and alcohol consumption (140-142). 
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Those data also support the concept that redox potentials respond to 
endogenous and exogenous disturbance and might be indicators reflecting 
combined effects of regulation of redox environment. 
Change of redox potential is associated with change of cellular status and 
biological process, which might promote development of multiple diseases. 
Cytosolic Eh(GSH/GSSG) becomes progressively oxidized during the life cycle 
when cells switch from proliferation (-240 mV) to differentiation (-200 mV) to 
apoptosis (-170 mV) (143). Oxidation of extracellular Eh(Cys/CySS) from -150 
mV to 0 mV stimulates monocyte adhesion, inhibits colorectal adenocarcinoma 
epithelial proliferation and increases oxidant-induced retinal pigment epithelial 
apoptosis (144-146). Oxidized extracellular Eh(Cys/CySS) stimulates pro-
inflammatory signaling in endothelial cells, while oxidized plasma 
Eh(GSH/GSSG) directly correlates with thickness of carotid intima-media 
thickness, both of which suggest increased chance of developing 
atherosclerosis (147, 148). Plasma Eh(GSH/GSSG) is more oxidized in diabetic 
patients (149). For chronic obstructive pulmonary disease (COPD) patients, 
plasma Eh(Cys/CySS) is more oxidized (150). Furthermore, loss of lung 
function correlates with the extent of plasma Eh(Cys/CySS) oxidation (150). 
Severity of human immunodeficiency virus (HIV) infection, which is represented 
by CD4-positve T cell count, also correlates with plasma Eh(Cys/CySS) (150). 
Reduced extracellular Eh(Cys/CySS) decreases mouse neuronal death via 
increasing GSH and decreasing ROS (151). Reduced extracellular 
18 
Eh(Cys/CySS) also reverses the loss of free reduced nicotinamide adenine 
dinucleotide (NADH) in mouse old and Alzheimer’s neurons, protecting against 
age-related Alzheimer's disease (152). Oxidized extracellular Eh(Cys/CySS) 
induces ROS generation, promotes extracellular signal-regulated kinase (ERK) 
phosphorylation and NF-kB expression via activating metabotropic glutamate 
receptor 5 (mGlu5), and stimulates inducible nitric oxide synthase (iNOS) 
expression in rat glioma C6 cells (153). The oxidized media conditioned by C6 
glial cells decrease tyrosine hydroxylase expression in mouse dopaminergic 
neuronal MN9D cells, which is neurotoxic and promotes Parkinson’s disease 
(153). However, reduced extracellular Eh(Cys/CySS) promotes migration and 
invasion of PC3 prostate carcinoma cells via increasing MMP9 activity and 
NOX1-mediated H2O2 production (154). Reduced Eh(Cys/CySS) also promotes 
proliferation of colon carcinoma Caco-2 cells via metalloproteinase-mediated 
epidermal growth factor receptor (EGFR) activation and downstream p44/p42 
mitogen-activated protein kinase (MAPK) phosphorylation (155). 
Overall, the effects of change of redox potential might be versatile and 
dependent on cells and tissues. Oxidizing redox potential might generally 
initiate diseases. Reducing redox potential might generally increase cellular 
defense against harmful stimulants, thus increasing cancer cell survival and 
promoting disease progression. However, whether oxidation or reduction is 
beneficial for patients is determined on a case-by-case basis and might be 
dependent on the disease course or stage. The underlying mechanisms are not 
19 
well studied and might involve a combination of disturbing intracellular redox 
environments, influencing post-translational modifications and functions of 
proteins and affecting multiple signal transduction pathways. 
Particularly, changes of redox potential contribute to lung fibrosis. Oxidized 
extracellular Eh(Cys/CySS) stimulates proliferation of primary mouse lung 
fibroblasts and fibronectin expression via activating protein kinase C, up-
regulating TGF-β1 and cAMP response element binding protein (CREB) (156). 
NF-kB and Smad3 levels are also increased (156). The pro-fibrotic effects 
require thiol/disulfide interaction as conjugating thiols with chemical reagents 
blocks fibronectin induction (156). In bleomycin-induced lung fibrosis mouse 
model, oxidation of plasma Eh(GSH/GSSG) coincides with the pro-inflammatory 
phase while oxidation of plasma Eh(Cys/CySS) occurs during the fibrotic phase 
(57). ELF Eh(Cys/CySS) is oxidized to a greater degree than plasma 
Eh(Cys/CySS) and occurs before the fibrotic phase (57). Those suggest 
oxidation of redox couples might precede appearance of the fibrotic phenotype 
and represent a predisposing state with increased susceptibility to injuries from 
internal and external detrimental exposures.  
Oxidative stress increases with aging and is considered an age-related 
defect. Aging is the most striking risk factor for IPF, and indicators of redox 
imbalance are observed in and contribute to IPF. Oxidation of redox couples 
accompanies aging in human plasma. Oxidation of redox couples also 
regulates multiple signaling pathways in vitro, including stimulation of pro-
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fibrotic cellular responses in mouse lung fibroblasts, and precedes bleomycin-
induced lung fibrosis in vivo. The downstream effects of oxidized redox potential 
have been explored while the upstream mechanism of whether and how redox 
potential are regulated remains unknown. Following study reveals the 
relationship between redox couples and mouse lung fibroblasts is reciprocal. 
Fibroblasts actively regulate their extracellular Eh(Cys/CySS) in culture (157). A 
set-point value is reached and maintained for both fibroblasts from young and 
old mice regardless of whether the initial incubating media are oxidizing or 
reducing (157). The only difference between young and old fibroblasts is that 
the set-point value is more oxidizing for old fibroblasts, which is consistent with 
increased susceptibility of pro-fibrotic responses (157).  
Slc7a11 expression is lower in old fibroblasts compared to young fibroblasts 
(157). It is the light chain subunit of a membrane-bound CySS/glutamate 
antiporter system Xc- (158). System Xc- imports CySS and exports glutamate 
with 1:1 exchange ratio. Inside the cells, CySS can be reduced to Cys, which 
is the rate-limiting component of GSH synthesis. Expression of Slc3a2, which 
is the other subunit of system Xc- and also known as 4F2 heavy chain (4F2hc) 
or CD98, is not different between young and old fibroblasts (157, 159, 160). 
Therefore, Slc7a11 might determine the activity of system Xc- and is considered 
to be a candidate to regulate extracellular Eh(Cys/CySS) in primary mouse lung 
fibroblasts. 
1.4 Specific aims 
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IPF develops insidiously. Honeycombing involves destruction of basement 
membrane and is not reversible. By the time patients are diagnosed, extensive 
fibrosis characterized by widespread fibrotic foci and honeycombing has 
already formed, there is no available treatment to reverse the fibrosis. Therefore, 
identifying subclinical stage of IPF will probably provide patients with the utmost 
benefits. Since change of redox potential might precede detectable lung fibrosis, 
it is critical to understand how redox potential is regulated and whether redox 
potential is targetable to modify extracellular and intracellular redox 
environments so that lung redox homeostasis is restored, and the susceptibility 
of fibrosis is not increased. 
This dissertation aims to investigate whether Slc7a11 mediates age-
dependent change of extracellular and intracellular redox potentials and how 
Slc7a11 affects intracellular signaling pathways in primary mouse lung 
fibroblasts. Redox potentials between fibroblasts from IPF patients and non-
IPF donors will be compared and the role of Slc7a11 in human fibroblasts will 
also be explored. 
Aim 1: To determine whether age-dependent Slc7a11 expression controls 
extracellular Eh(Cys/CySS) in primary mouse lung fibroblasts. 
My data indicate that Slc7a11 can be a potential controller of extracellular 
Eh(Cys/CySS) and therefore a switch of pro-fibrotic responses in fibroblasts. 
The experiments in Aim 1 will be composed of pharmacological and genetic 
manipulations of Slc7a11 expression to validate the regulatory role of Slc7a11. 
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Whether Slc7a11 controls the balance of Cys/CySS and GSH/GSSG redox 
couples and their redox potentials extracellularly and intracellularly will be 
explored. The efficacy of sulforaphane to induce Slc7a11 will be demonstrated 
to establish the potentiality of sulforaphane as a drug to restore redox 
homeostasis in further clinical trials. 
Aim 2: To uncover which protein cysteines and pathways are changed with 
aging and responsive to Slc7a11-dependent restoration of intracellular redox 
environment in primary mouse lung fibroblasts. 
Aging changes intracellular redox environment and protein oxidation. 
However, whether Slc7a11 affects intracellular redox environment, to what 
degree Slc7a11 reverses the effects of aging on intracellular redox environment, 
and what responses Slc7a11-dependent change of redox environment induce 
in fibroblasts remain unknown. Thiols of cysteine residues in multiple proteins 
are targets of various redox modifications. Change of cysteine redox state, 
which is defined as the ratio of oxidized to reduced form of a specific cysteine 
thiol, might determine the activity of the cysteine-containing protein and affect 
downstream signaling pathways. Redox proteomics will be applied in Aim 2 to 
identify these intracellular protein cysteines whose redox states are altered with 
aging and in response to Slc7a11 manipulation. Biological processes and 
functions those proteins are involved in will be analyzed to elucidate age-
dependent and Slc7a11-sensitive signaling pathways in fibroblasts. 
Aim 3: To compare SLC7A11 and redox environments in human lung 
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fibroblasts from non-IPF donors and IPF patients. 
The purpose of Aim 3 will be to demonstrate that the mechanisms explored 
in the first 2 Aims are directly applicable to humans. Primary human lung 
fibroblasts from patients with IPF and from non-IPF controls will be obtained. 
SLC7A11 expression, extracellular Eh(Cys/CySS), intracellular Eh(GSH/GSSG) 
and expression of pro-fibrotic genes will be measured in these human lung 
fibroblasts. This Aim will show the similarity between mouse and human lung 
fibroblasts and serve as an intermediate step between animal experiments and 
clinical trials.
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CHAPTER II 
 
AGE-DEPENDENT OXIDATION OF EXTRACELLULAR 
CYSTEINE/CYSTINE REDOX STATE (EH(CYS/CYSS)) IN MOUSE LUNG 
FIBROBLASTS IS MEDIATED BY A DECLINE IN SLC7A11 EXPRESSION 
 
2.1 Introduction 
Reversible reduction and oxidation (redox) of the sulfur-containing amino 
acid cysteine (Cys) is exploited for a large number of biological processes (87). 
Redox reactive Cys can be found as the free amino acid, as part of the thiol 
antioxidant glutathione (γ-glutamylcysteinylglycine; GSH), or as 
functional/regulatory sites within proteins (143). Cys and its oxidized form, 
cystine (CySS), constitute a redox couple that can be expressed in terms of its 
redox potential, or Eh value. Likewise, GSH and its disulfide form, abbreviated 
GSSG, comprise another redox couple. These 2 couples are functionally 
connected but differentially regulated (127). Cys and CySS are present in 
greater concentrations than GSH and GSSG outside of cells, whereas GSH 
and GSSG predominate within the intracellular compartment (161, 162). In 
addition, each couple and each compartment are maintained at different redox 
potentials (147). Therefore, it is important to specify which compartment is 
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being considered when reporting redox potentials. Both intracellularly and 
extracellularly Cys/CySS and GSH/GSSG function as redox buffers to maintain 
redox homeostasis (143) and resist or facilitate oxidation of protein thiols to 
change protein functions and transduce signals (163, 164). Thus, changes in 
redox potential can have a dramatic effect on cellular function. For example, 
oxidation of extracellular Eh(Cys/CySS) suppressed proliferation and inhibited 
signal transduction in Caco2 cells (155, 165), increased pro-inflammatory IL-1β 
in human monocytic U937 cells (166), and stimulated proliferation and pro-
fibrotic gene expression in mouse lung fibroblasts (156).  
Oxidation of the extracellular space is reflected in changes in plasma redox 
potentials. In vivo studies have shown that plasma Eh(Cys/CySS) was oxidized 
in mice with bleomycin-induced lung injury (57), and in rats with kainic acid and 
pilocarpine-induced epilepsy (167). In humans, plasma Eh(Cys/CySS) was 
found to be more oxidized in adults chronically exposed to arsenic (168), adults 
acutely exposed to acetaminophen (169), and in children with autism (170). 
Thus, oxidation of the extracellular environment, or redox stress, is associated 
with disease processes and environmental or pharmacological exposures.  
Aging is a risk factor for development of a number of chronic diseases. One 
way in which aging may promote disease development or progression is by 
changing the set-point of the redox buffering systems. Aging is associated with 
a steady oxidation of plasma Eh(Cys/CySS) (136), but the mechanisms 
responsible are unclear. Cells in culture maintain an Eh(Cys/CySS) remarkably 
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close to the redox potential of plasma (145, 155, 171), suggesting that cells are 
actively involved in controlling their immediate extracellular redox environment. 
Previous study showed that lung fibroblasts from old mice (24 months old) 
produced an extracellular Eh(Cys/CySS) that was more oxidized than that 
produce by their young counterparts (2 months old) (157).  
Differential gene expression analysis revealed that Slc7a11 was down-
regulated in old mouse lung fibroblasts (157). Slc7a11 (also called xCT) is the 
light chain of system Xc- which transports CySS into cells and exports 
glutamate with 1:1 as the exchange ratio (172). Previous studies have 
suggested that Slc7a11 expression is linked to control of the extracellular 
Cys/CySS redox state. Mice lacking Slc7a11 have a more-oxidizing 
extracellular Eh(Cys/CySS), as evidenced by an increase in their plasma CySS 
concentrations that is not balanced by a corresponding increase in plasma Cys 
(173). Conversely, stimulation of B cell differentiation is accompanied by an 
upregulation of Slc7a11 and an increase in extracellular Cys concentration 
(174). In the latter study there was also an increase in intracellular GSH, 
consistent with other studies showing that Slc7a11 activity supports intracellular 
GSH levels by supplying Cys, which is the rate-limiting amino acid for its 
synthesis (175). The purpose of the present study was to determine whether 
down-regulation of Slc7a11 in fibroblasts from old mice was sufficient to explain 
the oxidation of the extracellular redox environment associated with aging, and 
to determine whether synthesis of intracellular GSH was a pre-requisite for this 
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effect.  
2.2 Materials and methods 
2.2.1 Reagents 
Reagents were purchased from Sigma-Aldrich (St. Louis, MO) or Corning 
(Manassas, VA) unless otherwise specified. 
2.2.2 Primary lung fibroblasts culture 
Lung fibroblasts were isolated from young (3 months) or old (24 months) 
female C57BL/6 mice (157). Mouse lungs were harvested and cut into 1 mm 
sections (176). Those lung sections were washed with sterile phosphate-
buffered saline (PBS) and resuspended in RPMI-1640 with L-glutamine 
containing 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution 
(176). Those tissues were transferred to cell culture dishes and incubated in a 
humidified 5% CO2 incubator at 37°C for 7 to 21 days to let fibroblasts migrate 
out of tissues (176). Animal use was approved by the Institutional Animal Care 
and Use Committee of the University of Louisville. DMEM with 10% FBS and 
1% antibiotic-antimycotic solution were used for regular cell culture (176). 
Fibroblasts between passage numbers 8 and 15 were used in the experiments. 
2.2.3 Preparation of redox media 
Redox media refers to media with specific Cys and CySS concentrations to 
achieve a specific redox state. DMEM without Met or Cys was used to make 
redox media. For 0 mV (oxidizing) media, 99.75 μM CySS and 0.5 μM Cys were 
added. All redox media were freshly prepared immediately before use. 
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2.2.4 Pharmacological treatment of fibroblasts 
For sulforaphane experiments, primary lung fibroblasts from old mice were 
seeded in 6-well plates at the density of 1,000,000 cells/well in DMEM 
containing 10% FBS and 1% antibiotic-antimycotic solution. After 24 hours, the 
media was changed in the induction group to fresh DMEM with 5 μM 
sulforaphane. In the controls, media was changed to fresh DMEM. After 
incubation for 4 hours, media was changed to 0 mV redox media and incubated 
for another 24 hours. Afterwards, media was collected for HPLC analysis and 
cells for qPCR analysis. 
For sulfasalazine experiments, young fibroblasts were used. Twenty four 
hours after plating, media were changed to 0 mV redox media with or without 
300 μM sulfasalazine. Four hours later, cells and media were collected.  
For L-buthionine sulfoximine experiments, young fibroblasts were 
incubated with or without 20 µM L-buthionine sulfoximine for 24 hours followed 
by 4 hours 0 mV redox media incubation. Afterwards, cells and media were 
collected. 
2.2.5 Genetic manipulation of Slc7a11 expression in lung fibroblasts 
Plasmid transfection was used to over-express Slc7a11 in old fibroblasts, 
while siRNA was used to knock down Slc7a11 in young fibroblasts. Plasmid 
encoding mouse Slc7a11 was from Origene Technologies, Inc. (Rockville, MD), 
and siRNA was from Dharmacon (Lafayette, CO). Plasmid LacZ encoding for 
beta-D-galactosidase and non-targeted NT2 were used as plasmid and si-RNA 
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control. Two μg of plasmid and 30 pmol of siRNA were used for electroporation. 
Electroporation was conducted using Mode U-023 in NucleofectorTM 2b Device 
(Lonza, Allendale, NJ) following the protocol in the AmaxaTM Basic 
NucleofectorTM Kit for Primary Mammalian Fibroblasts (Lonza, Allendale, NJ). 
One million fibroblasts were used for each electroporation and then plated in 6-
well plates. Serum-free and antibiotic-free DMEM were used to incubate the 
transfected cells. After 24 hours recovery, DMEM were changed to 0 mV media 
for 4 hours incubation. Then, media and cells were collected. 
2.2.6 Media derivatization and HPLC analysis 
Collected media were centrifuged at 800g for 4 minutes to pellet the 
suspended fibroblasts. Five hundred μl cell-free media were combined with 500 
μl ice-cold 10% (w/v) perchloric acid (PCA), 0.2 M boric acid and 20 μM γ-
glutamyl glutamate (177). These samples were derivatized by iodoacetic acid 
and dansyl chloride, and then analyzed by HPLC (Waters Corporation, Millford, 
MA) (178). For derivatization, 300 μl of the media-PCA mixture were combined 
with 60 μl of freshly prepared 14.8 mg/ml sodium iodoacetate. Then, the pH of 
the solution was adjusted to 9.0 ± 0.2 with 1 M potassium hydroxide. The 
sample was incubated at room temperature for 20 minutes and mixed with 300 
μl of freshly prepared 20 mg/ml acetone-dissolved dansyl chloride. After that, 
the sample was vortexed and incubated in the dark at room temperature for 24 
hours. On the next day, 500 μl of chloroform were added and the solution 
underwent vortex for 10 seconds. The top aqueous layer was used for 
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concentration measurements by HPLC. Concentrations of Cys, CySS, GSH, 
GSSG, CySSG were measured by integration relative to the internal standard 
γ-glutamyl glutamate. Total Cys concentration = [Cys]+2*[CySS]+[CySSG] and 
total GSH concentration = [GSH]+2*[GSSG]+[CySSG]. Eh of Cys/CySS and 
GSH/GSSG were calculated according to the Nernst equation for pH 7.4: 
Eh(Cys/CySS) = -250+30*log([CySS]/[Cys]2); Eh(GSH/GSSG) = -
264+30*log([GSSG]/[GSH]2) (179).  
2.2.7 Measurement of Slc7a11, Gclc and Nqo1 mRNA level 
RNAqueous®-4PCR Kit (Thermo Fisher Scientific, Waltham, MA) was used 
for DNA-free RNA isolation from primary mouse lung fibroblasts. SuperScript™ 
VILO™ cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA) was used 
for cDNA synthesis. Real-time quantitative PCR (qPCR) was conducted to 
measure Slc7a11, Gclc, Nqo1 and Gapdh mRNA expression with TaqMan 
probes (TaqMan® Gene Expression Assay Mm00442530_m1, 
Mm00802655_m1, Mm01253561_m1, Mm99999915_g1; Applied Biosystems), 
according to the manufacturer’s protocol (TaqMan Universal Master Mix II; 
Applied Biosystems). Step One Plus Real Time PCR System (Applied 
Biosystems) was used for qPCR with the parameters: 50°C 2 minutes, 95°C 
10 minutes, followed by 40 cycles of 95°C 15 seconds and 60°C 1 minute. 
Results were analyzed using Step One Software version 2.3 (Applied 
Biosystems). The amplification curves were analyzed by the mathematical 
equation of the second derivative, and the amounts of Slc7a11, Gclc, Nqo1 
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mRNA expression were normalized to the housekeeping gene Gapdh mRNA 
expression. The 2-ΔΔCT method was used to calculate relative quantification 
(180). 
2.2.8 Measurement of Slc7a11 activity  
Slc7a11 activity was measured as the rate of glutamate release. Fresh 0 
mV media containing 100 µM CySS and 0 µM glutamate were added to cells, 
and aliquots of conditioned media were removed at 15-minute intervals. 
Glutamate concentrations in media were measured using the 
Glutamate/Glutamate Oxidase assay kit from Molecular Probes (Waltham, MA) 
according to manufacturer’s recommendations. L-glutamate was oxidized by 
glutamate oxidase to produce α-ketoglutarate, ammonia and hydrogen 
peroxide. L-alanine and L-glutamate-pyruvate transaminase were used to 
regenerate L-glutamate by transamination of α-ketoglutarate to amplify the 
signal. Large amounts of hydrogen peroxide were produced and reacted with 
the Amplex® Red reagent in a 1:1 stoichiometry to generate fluorescent 
resorufin that could be detected. 
2.2.9 Statistical analysis 
Data were presented as mean ± standard deviation. Significance was 
evaluated by one-way ANOVA and unpaired two-tailed t-test. Linear regression 
was used to assess differences between rates of glutamate release. 
2.3 Results 
2.3.1 Manipulation of Slc7a11 by pharmacological agents  
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Consistent with the previous studies (157), primary lung fibroblasts from old 
mice had lower expression of Slc7a11 (Figure 2.1.A) and more oxidized 
extracellular Eh(Cys/CySS) redox potential (Figure 2.1.B) relative to fibroblasts 
from young mice. To begin to assess whether expression level of Slc7a11 was 
responsible for the observed differences in the extracellular redox states of 
young and old fibroblasts, old fibroblasts were treated with sulforaphane, an 
Nrf2 inducer known to increase expression of Slc7a11 (181). Sulforaphane 
increased Slc7a11 expression in old cells to the level seen in young cells 
(Figure 2.1.A). Sulforaphane also reduced extracellular Eh(Cys/CySS) to the 
value seen in young cells (Figure 2.1.B). There was no significant difference in 
the concentration of CySS in the conditioned media from cultures of young and 
old fibroblasts (Figure 2.1.C). Rather, a decrease in the amount of Cys (Figure 
2.1.D) that accumulated in the media was responsible for the 30 mV oxidation 
of old fibroblasts conditioned media. 
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Figure 2.1 Sulforaphane treatment of old fibroblasts restored Slc7a11 
expression and extracellular Eh(Cys/CySS) to the levels seen in young 
fibroblasts. Primary lung fibroblasts from young and old mice were incubated in 
DMEM with or without 5 μM sulforaphane for 4 hours followed by 24 hours 
incubation in 0 mV redox media. (A) Slc7a11 mRNA expression, (B) 
extracellular Eh(Cys/CySS), (C) extracellular Cys concentration, and (D) 
extracellular CySS concentration, were measured as described in Materials 
and Methods. Data are expressed as mean ± standard deviation of 3 
independent replicates. * - Indicates p<0.05 compared to untreated young 
fibroblasts. 
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Extracellular glutathione concentrations were also different between 
cultures of young and old fibroblasts. GSH, GSSG and the mixed disulfide 
between CySS and GSH (abbreviated CySSG) were all lower in the conditioned 
media from old cells compared to young cells (Figure 2.2.A). There was a larger 
decrease in GSH than in GSSG; as a result, the redox potential of this couple 
(Eh(GSH/GSSG)) was 30 mV more oxidized in the old cultures than in the young 
(Figure 2.2.B). GSH was not present in the 0 mV redox media initially. Therefore, 
the appearance of GSH indicated that it was released from the cells. To facilitate 
analysis of GSH export, the total GSH pool size was calculated by combining 
GSH contributed by all 3 forms: GSH, GSSG and CySSG. As shown in Figure 
2.2.C, total GSH was 4-fold lower in old fibroblasts than in young fibroblasts. 
Sulforaphane treatment restored extracellular GSH, GSSG, CySSG, total GSH 
and Eh(GSH/GSSG) in old cultures to the levels seen in cultures of young 
fibroblasts (Figure 2.2.A-C). 
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Figure 2.2 Glutathione was less abundant and more oxidized in the conditioned 
media of old fibroblasts, and sulforaphane corrected these deficiencies. 
Primary lung fibroblasts from young and old mice were incubated in DMEM with 
or without 5 μM sulforaphane for 4 hours followed by 24 hours incubation in 0 
mV redox media. (A) CySSG, GSH and GSSG, were measured in the 
conditioned medium by HPLC. (B) Extracellular Eh(GSH/GSSG) was calculated 
from the Nernst equation. (C) Total GSH concentration was calculated 
according to the formula: Total Cys = CySSG + GSH + 2*GSSG. Data are 
expressed as mean ± standard deviation of 3 independent replicates. * - 
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Indicates p<0.05 compared to untreated young fibroblasts. 
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Sulforaphane is known to induce the expression of a number of antioxidant 
genes via its activation of the transcription factor Nrf2 (182). To determine the 
extent to which the effects of sulforaphane on extracellular Eh(Cys/CySS) are 
mediated by Slc7a11 as opposed to its other transcriptional targets, cells were 
first transfected with siRNA to knock down Slc7a11 and then treated with 
sulforaphane. The results in Figure 2.3 showed that extracellular Eh(Cys/CySS) 
no longer became more reduced in response to sulforaphane in cells depleted 
of Slc7a11 (Figure 2.3.A). Expression of Slc7a11 was still induced by 
sulforaphane in the knock down cells, but not to the level seen in control cells 
(Figure 2.3.B). In contrast, other Nrf2 target genes (Gclc and Nqo1) were 
induced equally well in both control and knock down cells (Figures 2.3.C and 
2.3.D). 
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Figure 2.3 Reduction of extracellular Eh(Cys/CySS) in response to 
sulforaphane is mediated by Slc7a11. Primary lung fibroblasts from old mice 
were transfected with siRNA targeting Slc7a11 (si-Slc7a11) via electroporation. 
Non-targeting siRNA was electroporated as control. Fibroblasts were plated, 
and 24 hours later the media were changed to fresh DMEM with or without 5 
μM sulforaphane for 4 hours. After that, media were changed to 0 mV redox 
media for 4 hours. (A) Extracellular Eh(Cys/CySS), (B) Slc7a11 mRNA 
expression, (C) Gclc mRNA expression, and (D) Nqo1 mRNA expression, were 
measured as described in the legends to Figures 2.1 and 2.2. Data are 
expressed as mean ± standard deviation of 3 independent replicates. * - 
Indicates p<0.05 between sulforaphane-treated and untreated fibroblasts. 
39 
Having shown that a drug that increased Slc7a11 expression also reduced 
extracellular Eh(Cys/CySS), I sought to demonstrate that the inverse was also 
true: that inhibition of system Slc7a11 activity would oxidize extracellular 
Eh(Cys/CySS). For this purpose, sulfasalazine, an inhibitor of CySS transport 
that acts on the Slc7a11 subunit of system Xc-, was used(183). As predicted, 
sulfasalazine treatment of young fibroblasts oxidized extracellular 
Eh(Cys/CySS) by 30 mV (Figure 2.4.A). This oxidation was due to a significant 
decrease in the concentration of extracellular Cys, while extracellular CySS 
concentration was unaffected by sulfasalazine (Figure 2.4.B and 2.4.C). 
Inhibition of Slc7a11 activity had no effect on accumulation of total GSH in the 
conditioned media (Figure 2.4.D). 
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Figure 2.4 Slc7a11 inhibition by sulfasalazine in young mice lung fibroblasts 
resulted in oxidation of extracellular Eh(Cys/CySS). Primary lung fibroblasts 
from young mice were incubated in 0 mV redox media with or without 300 μM 
sulfasalazine (SASP) for 4 hours. Conditioned media were collected for 
analysis by HPLC. (A) Eh(Cys/CySS), (B) Cys concentration, (C) CySS 
concentration and (D) total GSH concentration were determined as described 
in the legends to Figures 2.1 and 2.2. Data are expressed as mean ± standard 
deviation of 3 independent replicates. * - Indicates p<0.05 compared to 
untreated young fibroblasts. 
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Not only Slc7a11 mRNA, but also the activity of Slc7a11-mediated transport 
was lower in fibroblasts from old mice (Figure 2.5). Because Slc7a11 exports a 
glutamate for every CySS it imports, accumulation of glutamate in the media 
was measured as a function of time to assess transport activity. This approach 
avoided having to account for the multiple fates of CySS once imported into the 
cell. Using this approach, the pharmacological manipulations were 
demonstrated to translate to changes in activity. Sulforaphane increased 
Slc7a11 transporter activity (Figure 2.5.A), whereas sulfasalazine inhibited 
activity (Figure 2.5.B). 
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Figure 2.5 Slc7a11 transport activity was increased by sulforaphane and 
inhibited by sulfasalazine. (A) Glutamate release by old fibroblasts with or 
without sulforaphane treatment. Primary lung fibroblasts from old mice were 
incubated in DMEM with or without 5 μM sulforaphane for 4 hours followed by 
20 hours incubation in 0 mV redox media. After that, media were changed to 
fresh 0 mV media, and media was collected at 15 min, 30 min, 45 min and 60 
min for measuring extracellular glutamate as described in Materials and 
Methods. (B) Glutamate release by young fibroblasts with or without 
sulfasalazine treatment. Primary lung fibroblasts from young mice were 
incubated in 0 mV media with or without 300 μM sulfasalazine. Media were 
collected at 15 min, 30 min, 45 min and 60 min for measuring extracellular 
glutamate. Data are expressed as mean ± standard deviation of 3 independent 
replicates. * - Indicates p<0.05 between treated and untreated fibroblasts. 
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2.3.2 Modulation of Slc7a11 expression via genetic methods 
Because pharmacological agents can have off-target effects, I next 
attempted to verify the above results using transfection to overexpress and 
knock down Slc7a11 in old and young fibroblasts. Similar to the results with 
induction by sulforaphane, transfection of old fibroblasts with a Slc7a11-
encoding plasmid increased Slc7a11 mRNA expression by three-fold (Figure 
2.6.A) and reduced the extracellular Eh(Cys/CySS) by 30 mV (Figure 2.6.B). 
Conversely, siRNA-mediated knock down of Slc7a11 in young fibroblasts 
decreased Slc7a11 mRNA level by three-fold (Figure 2.6.C). Correspondingly, 
extracellular Eh(Cys/CySS) became 45 mV more oxidized after Slc7a11 knock-
down (Figure 2.6.D). The changes in extracellular Eh(Cys/CySS) were largely 
driven by differences in Cys concentrations. Neither overexpression nor knock 
down had a significant effect on extracellular CySS concentrations (Figure 2.7.A 
and 2.7.B). However, Slc7a11 over-expression in old cells significantly 
increased extracellular Cys from 2 μM to 5 μM while Slc7a11 knock-down in 
young cells significantly decreased extracellular Cys from 6 μM to 1 μM (Figure 
2.7.C and 2.7.D). Neither overexpression nor knock down of Slc7a11 had a 
significant effect on the accumulation of extracellular GSH (Figure 2.7.E and 
2.7.F). 
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Figure 2.6 Effect of genetic manipulation of Slc7a11 on extracellular 
Eh(Cys/CySS). Primary lung fibroblasts from old and young mice were 
transfected with either an Slc7a11-encoding plasmid (pSlc7a11) or siRNA 
targeting Slc7a11 (si-Slc7a11) via electroporation. Controls were electroporated 
with pLacZ or non-targeting siRNA. Fibroblasts were plated, and 24 hours later 
the media were changed to 0mV redox media for 4 hours. (A) Slc7a11 mRNA 
expression and (B) extracellular Eh(Cys/CySS) in old fibroblasts with and 
without overexpression of Slc7a11. (C) Slc7a11 mRNA expression and (D) 
extracellular Eh(Cys/CySS) of young fibroblasts with and without knock down of 
Slc7a11. Data are expressed as mean ± standard deviation of 3 independent 
replicates. * - Indicates p<0.05 compared to controls. 
45 
 
Figure 2.7 Overexpression of Slc7a11 increased, and knock down of Slc7a11 
decreased, extracellular Cys concentrations. Primary lung fibroblasts from old 
and young mice were transfected with either pSlc7a11 (overexpression) or si-
Slc7a11 (knock down), as described in the legend to Figure 2.4. (A and B) 
Extracellular CySS concentrations, (C and D) extracellular Cys concentrations, 
and (E and F) total extracellular GSH concentrations in old and young 
fibroblasts, respectively. Data are expressed as mean ± standard deviation of 
3 independent replicates. * - Indicates p<0.05 compared to controls. 
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Both Cys and GSH can be exported by cells and used to reduce an oxidized 
extracellular Eh(Cys/CySS). To determine whether metabolism of Cys to GSH 
is necessary for cells to reduce an oxidizing extracellular Eh(Cys/CySS), 
buthionine sulfoximine (BSO) was used to inhibit GSH synthesis by γ-
glutamylcysteinyl ligase. As shown in Figure 2.8, 24 hours pre-treatment with 
BSO dramatically lowered intracellular GSH (Figure 2.8.A). The inhibition of 
GSH synthesis by BSO also led to a dramatic decrease in extracellular GSH 
concentrations (Figure 2.8.B). BSO treatment had no effect on extracellular Cys 
concentration (Figure 2.8.C) or the ability of cells to restore extracellular 
Eh(Cys/CySS) within 4 hours of challenge with 0 mV media (Figure 2.8.D), 
suggesting that GSH synthesis was not required for the normalization of an 
oxidizing extracellular Eh(Cys/CySS). 
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Figure 2.8 Glutathione depletion with BSO did not affect extracellular Cys 
concentration or Eh(Cys/CySS). Primary lung fibroblasts from young mice were 
incubated in 0 mV redox media with or without 20 µM L-buthionine sulfoximine 
(BSO) for 24 hours. (A) Total intracellular GSH. (B) Total extracellular GSH. (C) 
Extracellular Cys concentration. (D) Extracellular Eh(Cys/CySS). Data are 
expressed as mean ± standard deviation of 3 independent replicates. * - 
Indicates p<0.05 compared to controls. 
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2.4 Discussion 
The current studies confirm the finding that Slc7a11 expression was lower 
in primary lung fibroblasts from old mice than in those from young mice, and 
that this was associated with increased oxidation of extracellular Eh(Cys/CySS) 
redox potential (157). Those findings have now been extended by investigating 
the mechanistic link between these two observations. Up-regulation of Slc7a11 
expression by either sulforaphane treatment or transient transfection was 
sufficient to restore the ability of lung fibroblasts from old mice to reduce their 
extracellular Eh(Cys/CySS) to the level achieved by those from young mice. 
Conversely, inhibition of Slc7a11 activity by either sulfasalazine treatment or 
siRNA-mediated knock down produced young fibroblasts that resembled old 
fibroblasts in terms of their extracellular redox potential. Taken together, these 
findings show that Slc7a11 activity is the major determinant of the extracellular 
redox environment produced and maintained by primary lung fibroblasts. 
In each of the studies presented here, Slc7a11 was positively correlated 
with extracellular Cys concentrations. This suggests that intracellular reduction 
of CySS to Cys, and the subsequent export of Cys, is limited by the rate of 
delivery of CySS to cells. Differences in Slc7a11 activity had no effect on 
extracellular CySS concentrations under the culture conditions used in this 
study. This is most likely a reflection of the process by which cells regulate their 
extracellular redox environment. CySS cannot be reduced to Cys in the 
extracellular space. Therefore, cells adjust the relative proportions of 
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extracellular CySS and Cys by importing CySS, reducing it to Cys, and then 
exporting Cys via system alanine-serine-cysteine (system ASC) (184-187). To 
achieve physiological redox potential of about -80 mV (136), only a fraction of 
the media CySS needed to be reduced to Cys. Because each molecule of CySS 
yields 2 molecules of Cys, very little CySS is consumed in the process of 
normalizing the extracellular redox potential. Thus, CySS import via Slc7a11 
appears to be the rate-limiting factor for intracellular Cys formation and export, 
just as it is rate-limiting for GSH synthesis in some cell types (188, 189).  
An increase in extracellular Cys, but not CySS, in response to increased 
Slc7a11 activity has been observed previously. Overexpression of Slc7a11 in 
Burkitt’s Lymphoma cells was associated with increased extracellular Cys 
concentrations (190), similar to my results. In contrast, knock out mice had 
elevated plasma CySS, but no change in plasma Cys (173). The discrepancy 
between these findings and my results with sulfasalazine or siRNA-mediated 
knock down of Slc7a11 may have been due to the fact that the fibroblasts used 
in the current studies do not completely lack Slc7a11, or it could be the 
presence of other cell types in the mice that may remove Cys from the plasma 
(191).  
Of the 3 component amino acids of GSH, Cys is usually present at the 
lowest concentrations within cells and limits the rate at which GSH can by 
synthesized (175). Therefore, changes in Slc7a11 activity can affect 
intracellular GSH production. In cancer cells, elevated Slc7a11 expression is 
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associated with increased resistance to chemotherapy drugs (192). Conversely, 
inhibition of CySS transport can sensitize cancer cells to radiation therapy (193). 
The age-related decrease in Slc7a11 expression observed in the current study 
may limit GSH synthesis and contribute to lower extracellular concentrations of 
GSH. 
CySS and GSH have many fates both extracellularly and intracellularly, 
complicating efforts to account for contributions of metabolism and transport to 
changes in concentrations in any given location. Extracellular GSH can be used 
to increase extracellular Cys concentrations by two mechanisms: it can undergo 
thiol-disulfide exchange with extracellular CySS to yield Cys and the mixed 
disulfide CySSG, or it can be catabolized enzymatically by gamma-
glutamyltransferase and dipeptidase to yield Cys and the other two component 
amino acids of GSH, glutamate and glycine (175).  GSH can also be oxidized 
to GSSG and used to glutathionylate extracellular proteins. Similarly, CySS can 
cysteinylate proteins. Extracellular Cys itself can be taken up by some cell types 
through other amino acid transporters such as systems ASC, EAAT and LAT2 
(194, 195). Once CySS is imported, it can be reduced to Cys either non-
enzymatically through thiol-disulfide exchange with GSH or enzymatically by 
Txnrd1 or Txndc17 (186). Intracellular Cys can be used to synthesize proteins 
or GSH, which can then by oxidized, glutathionylate proteins, conjugate to 
electrophilic metabolites, or be exported. Despite the complexity of these 
interconnected pathways, my data point to a rather straightforward relationship 
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between Slc7a11 activity and extracellular Eh(Cys/CySS). Importantly, GSH 
was not involved in regulation of extracellular Eh(Cys/CySS), and that 
accumulation of Cys in the extracellular space was directly related to the level 
of Slc7a11 activity.  
Extracellular GSH was less abundant and more oxidized in cultures of lung 
fibroblasts from old mice. Whereas sulforaphane treatment corrected these 
defects, Slc7a11 overexpression did not. A likely explanation for this 
discrepancy is that sulforaphane activates a much broader antioxidant 
response than does Slc7a11 overexpression alone. For example, my study 
confirmed that, in addition to Slc7a11 induction, sulforaphane upregulated the 
expression of Gclc, the catalytic subunit of the rate-limiting enzyme in GSH 
synthesis. Both Slc7a11 and Gclc are transcriptionally regulated by the 
transcription factor Nrf2. Sulforaphane is an electrophile that interacts directly 
with nucleophilic residues on Keap1, thereby activating Nrf2 (196). In cancer 
cells, sulforaphane can induce anticancer responses driven in part through 
production of reactive oxygen species via interactions with mitochondrial 
respiratory complex I (197). Oxidative stress produced in this way can promote 
the formation of 4-hydroxynonenal, an endogenous electrophilic activator of 
Nrf2 (198). However, untransformed cells, such as the primary fibroblasts used 
in the present study, are typically protected from the anticancer effects of 
sulforaphane (199). 
In conclusion, oxidative stress has been well recognized in aging. While 
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oxidative stress can be measured in many ways, my studies focused on 
oxidation of the extracellular Eh(Cys/CySS) redox potential. Oxidation of 
extracellular Eh(Cys/CySS) has been linked to age-dependent lung matrix 
remodeling and changes in the phenotype of lung fibroblasts (156, 157), as well 
as phenotypic changes in other cell types (144, 200, 201).  Identification of 
Slc7a11 as a critical factor in the regulation of the extracellular redox 
environment will undoubtedly lead to novel approaches to understanding the 
effects of aging in health and disease. 
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CHAPTER III 
 
REDOX STATES OF PROTEIN CYSTEINES IN PATHWAYS OF PROTEIN 
TURNOVER AND CYTOSKELETON DYNAMICS ARE CHANGED WITH 
AGING AND REVERSED BY SLC7A11 RESTORATION IN MOUSE LUNG 
FIBROBLASTS 
 
3.1 Introduction 
Aging has been proposed as a consequence of failure of redox networks to 
sustain biological functions (202). This redox theory of aging accounts for 
several hallmarks of aging, including altered intercellular communication, loss 
of proteostasis, epigenetic alterations and mitochondrial dysfunction (27, 202), 
because each of these is sensitive to changes in redox state of one or more of 
its constituent components. One convenient way to assess changes in systemic 
redox states is to measure the redox potential (Eh) of the cysteine/cystine 
(Cys/CySS) thiol/disulfide redox couple (Eh(Cys/CySS)). Human plasma 
typically has an Eh(Cys/CySS) of about -80 mV, and cells grown in culture 
condition their media to this same value (134, 157). As we age, plasma 
Eh(Cys/CySS) becomes progressively more oxidized (136), and cultured old 
cells condition their media to more oxidized values when compared to young
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cells (157). Thus, aging is associated with a disrupted redox environment and 
decreased ability to fight against oxidative stress. 
Previous studies showed that the expression of Slc7a11, the light chain of 
the CySS transporter system Xc-, was decreased in old mouse lung fibroblasts 
compared to that of young fibroblasts, concomitant with oxidation of 
extracellular Eh(Cys/CySS) that occurs with age (157, 203). Pharmacological 
induction and genetic overexpression of Slc7a11 restored extracellular balance 
of the Cys/CySS redox couple and its Eh(Cys/CySS) in a glutathione (GSH) 
synthesis-independent manner, confirming Slc7a11 is responsible for 
controlling extracellular Eh(Cys/CySS) in primary mouse lung fibroblasts (203). 
Previous studies also showed extracellular Eh(Cys/CySS) was associated with 
a variety of biological processes and diseases. For example, medium with 
oxidized Eh(Cys/CySS) induced the expression of TGF-β and fibronectin and 
stimulated the proliferation of mouse lung fibroblasts (156). Oxidized 
extracellular Eh(Cys/CySS) also promoted mitochondrial thioredoxin-2 
oxidation and induced reactive oxygen species (ROS) production in aortic 
endothelial cells (67). In C6 glial cells, oxidized Eh(Cys/CySS) increased 
phosphorylation of extracellular signal-regulated kinase (ERK) and expression 
of nuclear factor-κB (NF-κB) and inducible nitric oxide (iNOS) via activating 
metabotropic glutamate receptor 5 (153). Plasma Eh(Cys/CySS) was more 
oxidized in patients with chronic obstructive pulmonary disease compared to 
that in patients with normal lung function (150). Thus, Slc7a11 has the potential 
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to influence important intracellular signaling pathways and biological functions 
via controlling the extracellular redox environment. 
Once transported into cells by system Xc-, CySS is reduced to Cys, which 
is the rate-limiting component for GSH synthesis. GSH and Cys have the 
capacity to influence the redox states of individual intracellular proteins. 
Proteins contain cysteines that can be reversibly oxidized to disulfides or 
sulfenic acids. If a redox-sensitive cysteine is located in a catalytic or allosteric 
regulatory site, or a protein-protein or protein-DNA interaction domain, its redox 
state can determine the function of that protein. Many protein kinases have 
been shown to contain redox-sensitive cysteines. For example, oxidation of 
Cys797 to a sulfenic acid in the active site of EGFR increased its tyrosine kinase 
activity (204). In contrast, intramolecular disulfide bond between Cys297 and 
Cys311 and oxidation of Cys124 to a sulfenic acid inhibited the kinase activity 
of Akt2, demonstrating that predicting specific changes of biological function 
resulting from alterations in the redox states of cysteines is difficult, thereby 
requiring evaluation on a case-by-case basis and requiring experimental 
confirmation (205, 206). Furthermore, redox changes can affect structural 
proteins that contain redox-reactive thiols. In primary mouse lung fibroblasts, 
for example, cadmium exposure induced oxidation of cysteines of actin and 
actin-associated cytoskeleton proteins, thus changing actin dynamics via 
increasing filamentous actin formation and transporting destrin from cytoplasm 
to nucleus (207). 
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The large number and wide distribution of protein cysteines increase the 
functional flexibility of the proteome and play important roles in signal 
transduction, aging and disease (208). Redox proteomics can be used to define 
the redox states of all protein cysteines under a given set of conditions. Various 
redox proteomics methods have been developed, but they share some 
common features. In general, these methods rely on differentially labeling 
reduced and oxidized cysteines and separating the 2 forms from each other, 
followed by quantification of each form (209). This approach was recently used 
to study the change of redox states of proteins in brown adipose tissue of mice 
exposed to cold temperature (210). This method has been adapted for labelling 
reduced and oxidized cysteines to compare redox states between murine 
young and old lung fibroblasts, and old fibroblasts with Slc7a11 overexpression. 
Currently, there is no information about how Slc7a11 affects the redox state 
and function of the cysteine proteome. Furthermore, how aging changes the 
redox state of the cysteine proteome in primary mouse lung fibroblasts is 
unknown. This study aims to identify intracellular protein cysteines whose redox 
states are age-dependent, and to explore the potential biological functions of 
these cysteine-containing proteins. Considering that low Slc7a11 expression in 
old fibroblasts is responsible for the change of the extracellular redox 
environment with aging, I also aim to explore whether and to what extent 
restoration of Slc7a11 expression would reverse the age-dependent changes 
of intracellular redox environment and signaling pathways. 
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3.2 Materials and methods 
3.2.1 Reagents 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) or Corning 
(Manassas, VA) unless otherwise specified. 
3.2.2 Culture of primary mouse lung fibroblasts 
Primary lung fibroblasts were isolated from young (3 months) or old (24 
months) female C57BL/6 mice as described in Chapter 2 (176, 211). Animal 
maintenance and procedures of animal experiments were approved by the 
Institutional Animal Care and Use Committee of the University of Louisville. 
After isolation, fibroblasts were cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS) and 1% antibiotic-antimycotic solution in a humidified 
incubator with 5% CO2. Fibroblasts between passage numbers 10 and 15 were 
used in the experiments. 
3.2.3 Preparation of redox media with Eh(Cys/CySS) of 0 mV 
0 mV redox media were prepared from adding CySS and Cys to cysteine-
free and FBS-free DMEM to reach the final concentrations of 99.75 μM for 
CySS and 0.5 μM for Cys. All redox media were freshly prepared and used for 
fibroblast incubation immediately. 
3.2.4 Overexpression of Slc7a11 expression 
Plasmid encoding mouse Slc7a11 was purchased from Origene 
Technologies, Inc. (Rockville, MD). Two micrograms of plasmid were used to 
overexpress Slc7a11 in lung fibroblasts from old mice via electroporation. The 
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program of U-023 on the NucleofectorTM 2b Device (Lonza, Allendale, NJ) and 
the protocol of the AmaxaTM Basic NucleofectorTM Kit for Primary Mammalian 
Fibroblasts (Lonza, Allendale, NJ) were applied for electroporation. One million 
fibroblasts underwent transfection and were seeded in 6-well plates. 
Fibroblasts were recovered in antibiotic-free DMEM with 10% FBS. After 24 
hours, the media were changed to 0 mV redox media for 4 hours incubation. 
Finally, media and cells were collected for measuring extracellular 
Eh(Cys/CySS) via HPLC and redox states of cysteine residues of intracellular 
proteins, respectively. 
3.2.5 Media derivatization and high-performance liquid chromatography (HPLC) 
analysis 
Detailed procedures were described in Chapter 2 (203). Briefly, media were 
transferred to a tube containing the same amount of ice-cold solution consisting 
of 10% (w/v) perchloric acid, 0.2 M boric acid and 20 μM γ-glutamyl glutamate 
(177). Then, media were derivatized with iodoacetic acid and dansyl chloride 
for HPLC analysis (Waters Corporation, Millford, MA) (178). Calculation of 
Eh(Cys/CySS) was based on the Nernst equation for pH 7.4: Eh(Cys/CySS) = -
250+30*log([CySS]/[Cys]2) (134). 
3.2.6 Labeling of reduced and oxidized cysteine residues of intracellular 
proteins with different iodoacetyl tandem mass tags (iodoTMTs) 
My labeling method was developed based on the isobaric iodoTMTsixplex 
reagent. Each iodoTMT label contains a thiolate specific-reactive group for 
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labeling reduced thiols, a mass reporter with different numbers of isotope 
positions for distinguishing different tags in the mass spectrometry, and a mass 
normalizer for balancing the molecular weight. Proteins of fibroblasts in each 
well were collected and frozen in 300 μl of 10% trichloroacetic acid (TCA) before 
labeling. After thawing, proteins were centrifuged at 16,000 g at 4 °C for 15 min. 
The protein pellet was washed with ice-cold acetone. Then, the protein pellet 
was dissolved in 200 μl of denaturing buffer consisting of 200 mM Tris, 1 mM 
EDTA and 0.1% (w/v) SDS, pH 8.5. Immediately thereafter, 100 μl of dissolved 
proteins was added to a tube containing one of six iodoTMT reagents freshly 
dissolved in 10 μl methanol and incubated for 1 hour at 37°C. This step labels 
the reduced cysteines. Proteins were precipitated once again in TCA and 
washed with acetone to remove unincorporated iodoTMT reagent. Proteins 
were dissolved in 100 μl of denaturing buffer and 1 μl of 500 mM TCEP was 
added to reduce reversibly oxidized protein cysteine residues. The newly-
reduced cysteines were then labeled by adding the second iodoTMT label and 
incubating for 1 hour at 37 °C. Again, proteins were precipitated with TCA and 
washed with acetone to remove unincorporated iodoTMT. Finally, double-
labelled protein pellet was dissolved in 60 μl of denaturing buffer. 
3.2.7 Digestion, affinity purification and multiplexed liquid chromatography-
tandem mass spectrometry (LC-MS/MS) 
Detailed procedures were described here according to a previous study 
(212). The same amount of labelled proteins from different groups were mixed. 
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Then, trypsin was used to digest the proteins at 37 °C overnight. After digestion, 
peptides were lyophilized and dissolved in 100 μl of Tris-buffered saline (TBS). 
0.2 ml of anti-TMT resin beads (0.4 ml of 50% slurry) was used for enrichment 
of the digested peptides. Peptides were incubated with the beads at 4 °C 
overnight. Then, the beads were washed 3 times with 200 μl of TBS, followed 
by 3 times with 0.2 ml water. Finally, the bound peptides were eluted 3 times 
with 0.2 ml elution buffer. The elutes were then desalted with C18 spin column 
(Pierce, Rockford, IL), dried by speed vacuum, dissolved in 1% formic acid and 
analyzed by multiplexed LC-MS/MS. 
3.2.8 Ingenuity Pathway Analysis (IPA)  
Redox state of a cysteine residue in a protein was defined as the ratio of its 
oxidized form to reduced form. Peptides containing cysteine residues that had 
significant change of redox state with aging were selected. Among them, the 
redox states of cysteines in a subgroup of peptides were reversed by Slc7a11 
overexpression. Proteins containing peptides in this subgroup were used for 
IPA (http://www.ingenuity.com) and bioinformatic analyses. IPA predicts 
networks, canonical pathways and molecular functions associated with the 
input list of genes or proteins (213). Fold-changes of the redox states of 
cysteines between old and young fibroblasts for the above subgroup were used 
as IPA input. The false discovery rate (FDR) threshold was set at 0.05. 
3.2.9 Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway analysis 
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GO analysis is used for annotating genes and their products from 3 
categories, including biological process (BP), molecular function (MF) and 
cellular component (CC) (214). KEGG (www.genome.jp/kegg/) is a database 
for linking genomic information with functional information to achieve analysis 
of functions of genes systematically (215). Online Database for Annotation, 
Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) was 
used to conduct GO enrichment analysis and KEGG pathway analysis (216). 
GO and KEGG terms with a p-value < 0.05 were considered significantly 
enriched. 
3.2.10 Protein-protein interaction (PPI) network construction 
STRING database (http://www.string-db.org/) and Cytoscape 3.6.1 
(https://cytoscape.org/) were used to construct PPI network to explore 
functional associations between proteins (217, 218). The minimum required 
interaction score was medium confidence (≥ 0.4). 
3.3 Results 
3.3.1 Slc7a11 overexpression corrects extracellular Eh(Cys/CySS) in old 
fibroblasts 
My goal is to explore how aging affects redox states of intracellular cysteine 
residues of proteins, and to examine whether Slc7a11 overexpression in old 
cells reverses some, if not all, of those changes. Consistent with the previous 
studies in Chapter 2 (157, 203), primary lung fibroblasts from old mice showed 
lower Slc7a11 expression and more oxidized extracellular Eh(Cys/CySS) 
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compared to fibroblasts harvested from young mice (Figure 3.1). Genetic 
overexpression of Slc7a11 by plasmid in old fibroblasts successfully restored 
Slc7a11 expression and resulted in reduction of extracellular Eh(Cys/CySS) 
close to the levels seen in young fibroblasts, confirming the cell model for 
testing the effects of Slc7a11 on the redox environment had been reproduced 
(Figure 3.1). 
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Figure 3.1 Overexpression of Slc7a11 restored age-dependent oxidation of 
extracellular Eh(Cys/CySS) in old fibroblasts. (a) Slc7a11 mRNA expression 
and (b) extracellular Eh(Cys/CySS) were measured as described in materials 
and methods. Primary lung fibroblasts from young and old mice were isolated 
and old fibroblasts were transfected with Slc7a11-overexpressing plasmid 
(pSlc7a11). Fibroblasts were plated, and 24 h later the media were changed to 
0 mV redox media for 4 h. Data are expressed as mean ± standard deviation 
of 3 independent replicates. *- Indicates p < 0.05. 
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3.3.2 Identification of intracellular protein cysteines whose redox states 
changed with aging but were restored via Slc7a11 overexpression 
After collecting the media for measuring extracellular Eh(Cys/CySS), the 
cells were processed for intracellular cysteine redox proteomic analysis. Three 
different iodoTMT labels were used to label biologically reduced cysteine 
residues of proteins in young, old, and old Slc7a11-overexpressing fibroblasts 
(Figure 3.2). Next, TCEP was used to reduce reversibly oxidized cysteines, 
including disulfides, sulfenic acids, S-glutathionylation and S-nitrosylation. 
Then, 3 different tags were used to label those originally oxidized cysteines. 
Following digestion and enrichment via iodoTMT-affinity resin, peptides were 
analyzed via LC-MS/MS. A representative MS/MS spectrum is shown to 
demonstrate identification of peptides and quantification of oxidized and 
reduced forms from reporter ions (Figure 3.3). 
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Figure 3.2 Schematic flow chart of labeling redox-sensitive cysteines in 
peptides from young, old and old Slc7a11-overexpressing primary mouse lung 
fibroblasts using iodoTMT reagents. Detailed procedure was described in the 
main text. 
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Figure 3.3 Representative mass spectrum for determining Cys redox state. 
Peptides in the mixed samples were ionized and separated by LC-MS/MS. 
Specific Cys-containing peptides were selected after the first mass 
spectrometry based on the mass to charge ratio. Those peptides were further 
fragmented to smaller ions and detected by the second mass spectrometry as 
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shown in the upper panel. The region containing peaks of the reporter ions of 
the six iodoTMT labels (m/z 126-131) is shown in the lower panel. The peak 
intensity ratios of 129/128, 131/130 or 127/126 were defined as redox states 
for young, old or old Slc7a11-overexpressing primary mouse lung fibroblasts, 
respectively. 
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Over one thousand peptides were identified by mass spectrometry. To 
facilitate quantitative comparisons, the redox state of a specific cysteine residue 
was represented by the ratio of its oxidized portion to its reduced portion (redox 
state of cysteine = oxidized portion / reduced portion). To determine how the 
redox states of individual cysteines differed between old and young cells, a 
volcano plot representing statistical significance on the y-axis and fold-change 
of cysteine redox states on the x-axis was produced (Figure 3.4.a). For each 
cysteine residue, change of redox state with aging was represented by fold-
change (FC) of redox state in old cells relative to young cells (Old vs. Young FC 
= redox state of cysteine in old cells / redox state of cysteine in young cells) 
(Figure 3.4.a). Among all cysteines with detectable redox states, 12.6% 
(162/1282) peptides contained differentially oxidized cysteines with aging 
(above the dashed line representing p-value cutoff of 0.05) (Figure 3.4.a). Of 
those, 69% (112/162) were more oxidized in the old cells than in the young cells 
(above the dashed line and log2FC(Old/Young) > 0), while 31% (50/162) were 
more reduced with aging (above the dashed line and log2FC(Old/Young) < 0) 
(Figure 3.4.a). 
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Figure 3.4 Volcano plot showing peptides with age-dependent Slc7a11-
reversible Cys redox states. Each dot represented one Cys-containing peptide. 
(a) Proteins were differentially oxidized between old and young fibroblasts. The 
peptides above the dashed line were considered to contain cysteines whose 
redox states changed in response to aging (age-dependent Cys redox state). 
Those peptides belonged to 151 proteins. (b) Cys redox states were reversed 
by Slc7a11 overexpression. The proteins containing age-dependent Cys redox 
states were selected and plotted. Proteins below the dashed line were 
considered to contain Slc7a11-reversible Cys redox states. Altogether, 104 
proteins contained 116 cysteines whose redox states were reversed by Slc7a11 
overexpression. Three replicates of young, old and old Slc7a11-overexpressing 
fibroblasts were used to calculate the p-values. 
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The 162 peptides whose redox states changed with aging belonged to 151 
proteins. These 151 proteins were selected to further explore whether their 
redox states were reversible via Slc7a11 overexpression. Reversibility of age-
dependent changes of redox state was assessed by comparing the redox state 
in old Slc7a11-overexpressing cells relative to young cells (Old Slc7a11 
Overexpression vs. Young FC = redox state of cysteine in old Slc7a11-
overexpressing cells / redox state of cysteine in young cells) (Figure 3.4.b). 
Noticeably, 71.6% (116/162) of age-dependent changes of cysteine redox 
states were reversible via Slc7a11 overexpression (below the dashed line) 
(Figure 3.4.b). The majority of Slc7a11-dependent redox-sensitive cysteines 
(93 of 116, or 80%) were more oxidized in old cells, but a substantial number 
(23 of 116, or 20%) were more reduced in old cells. The 116 Slc7a11-dependent 
cysteine-containing peptides belonged to 104 distinct proteins, with one protein 
containing both oxidized and reduced cysteines. Those 104 proteins 
constituted the majority (104 of 151, or 69%) of the age-dependent redox-
modified proteins. 
The above observations indicated that decreased expression of Slc7a11 
with aging might significantly contribute to the age-dependent global changes 
observed in the redox states of the intracellular cysteine proteome in primary 
mouse lung fibroblasts. These 104 proteins with Slc7a11-dependent redox-
sensitive cysteines were focused on to further explore their potential biological 
functions using bioinformatics analyses. 
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3.3.3 Ingenuity Pathway Analysis (IPA), Gene Ontology (GO) and pathway 
enrichment analyses and protein-protein interaction (PPI) network analysis of 
proteins with Slc7a11-reversed redox-sensitive cysteines 
IPA showed that the most significantly enriched pathways related to 
Slc7a11-dependent redox-sensitive proteins were eukaryotic translation 
initiation factor 2 (EIF2) signaling, actin cytoskeleton and integrin-linked kinase 
(ILK) signaling, and protein ubiquitination pathway, which represented protein 
synthesis, cellular structure and communication, and protein ubiquitin-
proteasome-mediated degradation, respectively (Table 3.1). Three actin-
associated cytoskeleton proteins, TLN1, FLNB and PPP2CA, contained 
multiple redox-sensitive cysteines, indicating that actin dynamics and 
communication between cell membrane and intracellular cytoskeleton were 
prone to age-related oxidative stress and, importantly, that Slc7a11 
overexpression restored such redox effects of aging (Table 3.1). Interestingly, 
not all cysteine residues became more oxidized with aging. On the contrary, 
some became more reduced (Table 3.1), indicating that although aging 
promoted overall oxidation of the redox environment, the redox states of distinct 
components of the intracellular cysteine proteome were differentially regulated 
instead of simply being oxidized. Slc7a11 overexpression not only reduced age-
dependent oxidation of proteins, but also oxidized age-dependent reduction of 
certain proteins, suggesting that Slc7a11 influences the cysteine proteome 
indirectly via restoring the global intracellular redox environment rather than 
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interacting directly with individual redox-sensitive proteins. 
GO is a collection of terms describing gene functions and the relationship 
between the terms. It consists of 3 aspects: biological process, molecular 
function and cellular component. Consistent with IPA, GO annotation for 
biological process revealed that Slc7a11-dependent redox-sensitive proteins 
were enriched in cell adhesion, initiation and regulation of protein translation, 
organization of actin cytoskeleton and proteolysis (Table 3.2). Other significant 
enriched terms related to biological process involved RNA processing, cellular 
response to stimuli (e.g. virus) and oxidation-reduction processes (Table 3.2). 
Furthermore, Slc7a11 affected the redox states of proteins with molecular 
function related to the binding of poly(A) RNA, cellular adhesion-related 
cadherin, actin, ATP or other proteins (Table 3.3). Related to the GO cellular 
component, enriched items included extracellular exosome, cell-cell adherens 
junctions and cytoplasm (Table 3.4). Finally, KEGG pathways were mainly 
enriched in carbon metabolism and amino acids biosynthesis, ribosome and 
proteasome, tight and adherens junctions, and focal adhesion (Table 3.5). 
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Table 3.1. Ingenuity Pathway Analysis (IPA) indicated proteins whose redox 
states were restored by Slc7a11 overexpression were enriched in pathways of 
protein turnover and cytoskeleton signaling. The top 3 most significant enriched 
pathways were protein synthesis pathway, protein ubiquitin-proteasome-
mediated degradation pathway and actin cytoskeleton signaling / integrin-linked 
kinase (ILK) signaling. Some proteins contained more than 1 redox-sensitive 
Cys residue. Some Cys residues became more oxidized with aging while others 
became more reduced. 
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Table 3.2 GO-based biological process analysis of proteins whose redox states 
were rescued by Slc7a11 overexpression in old fibroblasts. Fisher’s exact test 
p-values for all the items shown were lower than 0.05. 
 
 
 
 
 
 
 
 
 
 
Term Count p-value -log10 (p-value) 
cell-cell adhesion 11   0.000             7.197  
translation 11   0.000             4.274  
RNA splicing 8   0.000             3.526  
tricarboxylic acid cycle 4   0.000             3.319  
platelet aggregation 4   0.001             2.971  
mRNA processing 8   0.002             2.786  
RNA secondary structure unwinding 4   0.002             2.757  
translational initiation 4   0.003             2.529  
cellular response to peptide hormone stimulus 3   0.007             2.147  
formation of translation preinitiation complex 3   0.008             2.112  
establishment or maintenance of cell polarity 3   0.009             2.047  
response to virus 4   0.010             1.994  
pentose-phosphate shunt, non-oxidative branch 2   0.026             1.581  
oxidation-reduction process 9   0.027             1.564  
actin cytoskeleton reorganization 3   0.031             1.507  
isocitrate metabolic process 2   0.031             1.503  
proteolysis involved in cellular protein catabolic process 3   0.037             1.433  
positive regulation of translation 3   0.037             1.433  
neuron projection development 4   0.038             1.422  
actin cytoskeleton organization 4   0.040             1.399  
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Table 3.3 GO-based molecular function analysis of proteins whose redox states 
were rescued by Slc7a11 overexpression in old fibroblasts. Fisher’s exact test 
p-values for all the items shown were lower than 0.05. 
 
 
 
 
 
 
 
 
 
 
Term Count p-value -log10 (p-value) 
poly(A) RNA binding 39   0.000            20.191  
cadherin binding involved in cell-cell adhesion 20   0.000            15.060  
enzyme binding 13   0.000             5.841  
actin binding 12   0.000             5.558  
actin filament binding 8   0.000             5.054  
RNA binding 16   0.000             4.598  
protein complex binding 11   0.000             4.521  
protein binding 42   0.000             4.517  
nucleotide binding 25   0.000             3.935  
protein domain specific binding 9   0.000             3.682  
GTP binding 9   0.001             2.878  
ATP binding 19   0.001             2.826  
protein kinase binding 9   0.003             2.540  
ATP-dependent RNA helicase activity 4   0.005             2.284  
GTPase activity 6   0.006             2.206  
oxidoreductase activity 10   0.006             2.191  
ADP binding 3   0.017             1.768  
Rac GTPase binding 3   0.022             1.662  
endopeptidase activity 4   0.025             1.610  
nucleoside binding 2   0.027             1.561  
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Table 3.4 GO-based cellular component analysis of proteins whose redox 
states were rescued by Slc7a11 overexpression in old fibroblasts. Fisher’s 
exact test p-values for all the items shown were lower than 0.05. 
 
 
 
 
 
 
 
 
 
 
Term Count p-value -log10 (p-value) 
extracellular exosome 57   0.000            23.688  
cell-cell adherens junction 20   0.000            14.949  
cytoplasm 72   0.000            14.704  
focal adhesion 16   0.000             9.092  
myelin sheath 12   0.000             8.558  
extracellular matrix 13   0.000             7.639  
cytosol 28   0.000             7.085  
intracellular ribonucleoprotein complex 12   0.000             6.291  
spliceosomal complex 8   0.000             5.304  
actin cytoskeleton 9   0.000             5.162  
cytoplasmic ribonucleoprotein granule 5   0.000             4.983  
cortical cytoskeleton 5   0.000             4.801  
stress fiber 6   0.000             4.700  
cytoskeleton 18   0.000             4.543  
perinuclear region of cytoplasm 14   0.000             4.457  
protein complex 13   0.000             4.216  
nucleus 49   0.000             4.123  
extracellular vesicle 5   0.000             4.002  
catalytic step 2 spliceosome 6   0.000             3.947  
proteasome complex 5   0.000             3.498  
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Table 3.5 KEGG pathway analysis of proteins whose redox states were rescued 
by Slc7a11 overexpression in old fibroblasts. Fisher’s exact test p-values for all 
the items shown were lower than 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Term Count p-value -log10 (p-value) 
Carbon metabolism 8   0.000             4.183  
Spliceosome 7   0.001             2.972  
Tight junction 7   0.001             2.873  
Citrate cycle (TCA cycle) 4   0.003             2.569  
Salmonella infection 5   0.005             2.317  
Proteasome 4   0.007             2.147  
Biosynthesis of antibiotics 7   0.011             1.955  
Adherens junction 4   0.025             1.597  
Biosynthesis of amino acids 4   0.031             1.507  
Proteoglycans in cancer 6   0.033             1.484  
Focal adhesion 6   0.035             1.453  
Ribosome 5   0.039             1.414  
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PPI network demonstrates the interactions between proteins in a 
straightforward and visualized way. Proteins with functional connections are 
clustered. Three clusters were identified from the PPI network (Figure 3.5). The 
upper left cluster was associated with cytoskeleton and cellular interaction, 
including actin signaling and integrin-linked kinase (ILK) signaling (Figure 3.5). 
The upper right cluster was involved in protein translation pathways, including 
EIF2 signaling (Figure 3.5). The lower cluster was related to protein 
ubiquitination and proteasome-mediated degradation (Figure 3.5). Those data 
were consistent with the IPA results and suggested that, by reversing the 
intracellular redox environment, Slc7a11 was able to block the age-dependent 
changes of redox states of protein cysteines in pathways of cytoskeleton 
dynamics and protein turnover. 
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Figure 3.5 Protein-protein interaction (PPI) network showed proteins with age-
dependent Slc7a11-responsive cysteines were clustered in IPA-predicted 
pathways. The upper left cluster was associated with cytoskeleton and cellular 
interaction, including actin signaling and integrin-linked kinase (ILK) signaling. 
The upper right cluster was associated with protein translation, including 
eukaryotic translation initiation factor 2 (EIF2) signaling. The lower cluster was 
related to protein ubiquitination and degradation. Proteins that contained age-
dependent oxidized, reduced, or both oxidized and reduced cysteines were 
shown in round, triangular or round rectangular boxes, respectively. 
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3.4 Discussion 
The current study confirms the role of Slc7a11 in mediating age-dependent 
oxidization of extracellular Eh(Cys/CySS) and extends these findings to include 
the impact of changes in Slc7a11 expression on the redox states of multiple 
intracellular proteins. Proteins related to the cytoskeleton or involved in protein 
degradation and protein synthesis are differentially oxidized in old murine lung 
fibroblasts as a result of lower Slc7a11 expression. Slc7a11 overexpression not 
only reduces proteins that become oxidized with aging, but also oxidizes certain 
proteins that are reduced with aging. Thus, targeting Slc7a11 for redox 
regulation might be a better approach than simply supplementing with 
antioxidants to re-establish redox homeostasis in aging and diseases. 
The redox states of particular cysteines associated with actin cytoskeleton 
signaling and ILK signaling are age-dependent but can be restored with 
Slc7a11 overexpression. Integrins mediate cell-cell and cell-matrix interactions, 
thereby linking extracellular matrices with the intracellular cytoskeleton. Talin 
and alpha-actinin, which are components of focal adhesion complexes (219, 
220), are shown in Chapter 3 to contain cysteines whose redox states are 
oxidized with aging. These changes might impact integrin-mediated signaling 
or mechanotransduction through alterations in cell stiffness, a process 
considered critical for promoting aberrant lung remodeling after injury and 
fibrosis (221, 222). Others have shown that cytoskeletal proteins are oxidized 
with aging. Protein carbonylation is an irreversible oxidative modification that is 
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increased in the brains of old senescence-accelerated-prone 8 (SAMP8) mice 
compared to the brains of young mice (223). In particular, collapsin response 
mediator protein-2 (CRMP-2), which is involved in cytoskeletal remodeling, 
microtubule assembly and cell migration, and alpha-spectrin, which interacts 
with actin to form a scaffold to maintain cytoskeletal stability and flexibility, are 
more oxidized (224). Thus, the actin cytoskeleton system might be a major 
target of age-dependent redox modification. S-glutathionylation is a form of 
reversible oxidation of cysteines. Actin contains cysteines with different degrees 
of S-glutathionylation that are flexibly deglutathionylated via glutaredoxin in 
response to stimuli (225). Glutaredoxin-mediated changes of cysteine S-
glutathionylation may regulate actin polymerization (226). These findings are 
considered important as the actin cytoskeleton is believed to play critical roles 
in fibroblast differentiation, myofibroblast contraction, focal adhesion complex 
formation, extracellular matrix remodeling, mechanical to biochemical signal 
transduction, and gene transcription, which are all important biological 
processes proposed to be involved in tissue fibrogenesis and maladaptive 
wound healing (227). In human skin fibroblasts, disassembly of actin 
cytoskeleton results in disruption of the TGF-β signaling pathway with 
subsequent collagen production, thus promoting skin aging (228). These 
findings further support the idea that the function of the actin cytoskeleton 
system is redox-sensitive, and its disruption might be associated with aging-
related degeneration and disease development. 
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Loss of proteostasis is a hallmark of aging (27). Proteostasis (from the 
terms protein and homeostasis) refers to the balance among the processes of 
protein synthesis, folding, trafficking and degradation. Redox modulation has 
been shown to affect protein folding and trafficking (229, 230). Disruption of 
proteostasis can result in deposition of protein aggregates and be harmful for 
cell survival (231, 232). Protein degradation by the proteasome changes with 
aging and is regulated by redox modulation, especially thiol oxidation (233, 234). 
Here, three age-oxidized cysteines in proteasome 26S subunit and one age-
reduced cysteine in heat shock protein 70 (HSP70) were identified, providing 
further evidence for the idea that the 26S proteasome is vulnerable to oxidative 
stress, and that its chaperone HSP70 responds to redox regulation (235, 236). 
The implications of age-dependent changes of protein redox states in the 
promotion of aging-associated diseases require further exploration. However, 
studies in Chapter 3 suggest that they are important and are in line with other 
observations. For instance, in the hippocampi of patients with Alzheimer 
disease (AD), peptidyl-prolyl cis-trans isomerase 1 (Pin 1), which catalyzes 
isomerization of neuronal cytoskeleton protein tau, becomes more oxidized 
(237). Ubiquitin carboxyl terminal hydrolase L-1 (UCHL-1) is involved in 
proteasome-mediated protein degradation, and its oxidation in AD disrupts the 
ubiquitination/de-ubiquitination balance and results in accumulation of 
dysfunctional proteins (237). Furthermore, proteins in the cell structural and 
proteasomal pathways are oxidatively modified in Parkinson disease (238). 
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Others have identified cysteine redox modifications that affect proteostasis. 
For example, S-glutathionylation of multiple cysteine residues results in 
increased accessibility of proteasomal active center and increased proteolytic 
activity (239). In this chapter, several other novel reversible redox-sensitive 
cysteines that might also influence proteasomal activity were identified. 
Whether proteosomal activity is increased or decreased depends on both the 
location and specific form of the redox modification being evaluated, thereby 
requiring experimental exploration in the future. Nevertheless, observations in 
Chapter 3 suggest that both cytoskeleton and proteasomal pathways are 
susceptible to age-related oxidative stress, and that redox modulations of 
cysteines might be an important post-translational mechanism responsible for 
age-dependent change of protein functions in those pathways. 
Protein synthesis was also found to be disrupted with aging and modified 
by Slc7a11-associated change of the redox environment. Compared to 
relatively well studied age-dependent protein degradation, how protein 
synthesis is altered with aging remains to be explored. My study found that 
aging was associated with changes of redox states of cysteines in EIF2 
signaling, including EIF4E, RPS6 and RPL9. These three proteins regulate 
protein synthesis in aging (240). The concentration and activity of eukaryotic 
translation initiation factors (eIFs) and the abundance of ribosomes are 
decreased with aging, resulting in an overall decrease in protein synthesis (241). 
These and the identification of several other age-dependent cysteines in other 
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parts of eIFs and ribosomes suggest that cysteine redox modifications mediate 
age-dependent defects detected in the protein synthesis machinery. The 
function of eIF2, for instance, is to load methionyl-tRNA to 40S ribosomal 
subunit, which is the first step of 43S preinitiation complex assembly (242). The 
function of eIF4E is to bind with the 5’ cap of mRNAs and mediate recruitment 
and attachment of 43S preinitiation complex (243). Those two steps determine 
the rate of protein synthesis. Phosphorylation of those initiation factors and their 
regulatory factors have been shown to control protein synthesis (244, 245). 
Similar to phosphorylation, redox modifications might represent another post-
translational mechanism capable of affecting the efficacy of protein synthesis. 
This idea is further supported by a recent study that revealed several H2O2-
sensitive thiols in proteins involved in the general translation machinery, and 
the subsequent attenuation of protein synthesis via such redox modulation 
(246). More studies are needed to further elucidate this redox control of protein 
synthesis pathways. 
Perhaps the most important finding of Chapter 3 is that Slc7a11 
overexpression may restore the protein redox microenvironments. Accordingly, 
one could predict that alterations in Slc7a11 expression or activity would lead 
to diseased states. Consistent with this idea, others reported that increase of 
Slc7a11 was part of the signatures of senescence inflammatory responses in 
intestinal epithelial cells (247). In peripheral white blood cells from 
schizophrenia patients, Slc7a11 expression was lower compared to those from 
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healthy donors (248). In tissues of non-small cell lung cancer, Slc7a11 
expression was higher (249). In glioma cells, the C-terminus of EGFR directly 
interacts with the central part of Slc7a11 and stabilizes Slc7a11 cell surface 
expression (250), thereby suggesting a role in oncogenic signaling. CD44 
variant directly interacts with Slc7a11 in pulmonary artery endothelial cells 
suggesting a role in vascular remodeling (251). Those interactions further 
complicate the potential biological roles of Slc7a11. It is unclear whether and 
how Slc7a11 expression changes in different cell types and whether such 
change affect the progression of aging or disease development differently. 
Although the upstream or downstream pathways of Slc7a11 might be different, 
the universal underlying mechanism is usually associated with Slc7a11-related 
change of redox environment, suggesting redox modulation might play a central 
role in controlling multiple biological processes and signaling pathways. 
Slc7a11 provides cells with Cys to support GSH synthesis. Therefore, one 
of the functions of Slc7a11 activity may be to support reduction of oxidized 
proteins by providing an essential co-factor for glutaredoxins (94). 
Glutaredoxins preferentially reduce glutathionylated proteins, whereas 
thioredoxins more efficiently reduce protein disulfides and sulfenic acids and 
are involved in de-nitrosylation of cysteines (87, 252-255). The link between 
Slc7a11 activity and thioredoxin-dependent protein reduction is not as direct as 
it is for glutathione-dependent processes, but an increase in GSH synthesis 
may decrease the overall burden on the thioredoxin system. The results in 
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Chapter 3 showed that while most cysteines became more oxidized in lung 
fibroblasts from aged mice, some became more reduced, and Slc7a11 
overexpression reversed redox states of both oxidized and reduced cysteines, 
supporting the idea that Slc7a11 manipulation targets intracellular redox 
signaling pathways rather than simply decreases overall oxidative stress. This 
might provide novel insight for combatting oxidative stress associated with 
aging and age-related aberrant wound healing. 
In conclusion, aging is associated with disruption of the intracellular redox 
environment represented by changes in the redox states of cysteines in 
fundamental pathways including protein turnover and cytoskeleton organization. 
Slc7a11 is a critical factor not only for regulating the extracellular redox 
environment, but also for controlling the intracellular redox environment. 
Targeting Slc7a11 can reverse age-dependent effects of oxidative stress on 
intracellular signaling pathways and lead to novel approaches to fighting 
against oxidative stress in age-related diseases.
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CHAPTER IV 
 
DECREASED SLC7A11 IS ASSOCIATED WITH OXIDATION OF 
EXTRACELLULAR CYSTEINE/CYSTINE REDOX STATE (EH(CYS/CYSS)) 
IN HUMAN LUNG FIBROBLASTS: A POTENTIAL SUSCEPTIBILITY STATE 
FOR IDIOPATHIC PULMONARY FIBROSIS 
 
4.1 Introduction 
Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial 
lung disease (256). It is characterized by irreversible destruction of alveoli, 
accumulation of aberrant matrix proteins in the lung interstitium, and remodeling 
of lung tissue resulting in scarring (257). The main clinical symptoms are dry 
cough and worsening shortness of breath, and the physical signs include 
bibasilar pulmonary crackles and finger clubbing (3). Oxygen supplementation 
is often needed as pulmonary function declines. The burden of IPF is not 
negligible. Over 180,000 Americans are currently affected by IPF, and the 
incidence as well as prevalence is still increasing worldwide (6, 258). IPF is 
insidious and progressive, usually diagnosed at later stages because of its 
chronic and non-specific nature. Even though the progression of IPF can be 
decelerated by pirfenidone or nintedanib, it’s still lethal because no intervention 
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has been proved to halt or reverse the fibrosis (18, 19). Furthermore, IPF mainly 
affects people from 55 to 75 years of age. The median age at diagnosis is 66 
and the median survival time is 3 to 5 years (12, 259). As the world population 
is aging, it is imperative to explore new diagnostic approaches for detecting IPF 
during its initial stage or new treatment options capable of reversing the fibrotic 
process. Thorough understanding of the mechanisms underlying IPF on the 
cellular and molecular levels is fundamental for developing innovative 
diagnostic biomarkers and effective treatments.  
Lung fibroblasts from IPF patients are different than those from non-IPF 
donors. Fibroblasts are the effector cells that produce excessive extracellular 
matrix proteins and manifest a fibrotic phenotype in IPF. IPF fibroblasts show 
decreased proliferation, decreased telomere length, enlarged morphology, 
increased resistance to apoptosis, increased expression of senescent markers 
(β- galactosidase, p16, p21, p53), and increased cytokine production 
(interleukin-6, interleukin-1β, fibroblast growth factor 2) belonging to the 
senescence-associated secretory phenotype (SASP), all of which are 
characteristics of cellular senescence (29, 260). Furthermore, media from 
senescent fibroblasts stimulate the expression of α-smooth muscle, collagen 
and fibronectin in non-senescent fibroblasts, indicating that senescent 
fibroblasts are pro-fibrotic and fibroblast senescence might play a key role in 
mediating IPF (261). 
Redox homeostasis is disrupted in IPF fibroblasts. For example, 
90 
mitochondrial dysfunction has been documented in IPF fibroblasts, including 
over-production of reactive oxygen species (ROS), up-regulation of genes 
related with mitochondrial synthesis and electron transport chain, increased 
mitochondrial DNA content and increased activity of mammalian target of 
rapamycin complex 1 (mTORC1), a mitochondrial homoeostasis mediator (111). 
IPF fibroblasts also express increased NADPH (reduced nicotinamide adenine 
dinucleotide phosphate) oxidase 4 (NOX4) (96). Expression of nuclear factor, 
erythroid 2 like 2 (NRF2), a major regulator of multiple anti-oxidant genes, is 
absent in fibroblast foci of IPF lung tissue (96). Both mitochondrial dysfunction 
and disturbance of the NOX4-NRF2 axis may promote fibroblast senescence 
and differentiation into myofibroblast and myofibroblast apoptosis resistance 
resulting in increased susceptibility to lung fibrosis after injury (96, 111). 
Redox couple together with its redox potential is another type of readily 
available biomarker of redox environment. Cysteine (Cys) and its oxidized form, 
cystine (CySS), constitute the major extracellular redox couple. 
Glutathione/glutathione disulfide (GSH/GSSG) is the major intracellular redox 
couple. Previous studies show extracellular Cys/CySS redox potential 
(Eh(Cys/CySS)) is more oxidized for cultures of fibroblasts from old mice 
compared to young mice (157). Oxidation of extracellular Eh(Cys/CySS) 
promotes pro-fibrotic responses of primary mouse lung fibroblasts, including 
activation of TGF-β/Smad signaling and induction of extracellular matrix 
proteins, such as fibronectin (156). Plasma Eh(Cys/CySS) and Eh(GSH/GSSG) 
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are progressively oxidized with aging in humans (137). Considering aging is the 
biggest risk factor for IPF, oxidation of redox couples might potentially mediate 
the effects of aging on promoting lung fibrosis. In the bleomycin-induced lung 
injury murine model, oxidation of plasma Eh(Cys/CySS) coincides with fibrosis 
while oxidation of plasma Eh(GSH/GSSG) precedes the appearance of fibrosis 
(57). Follow-up study in the mouse lung fibroblasts demonstrates that solute 
carrier family 7 (cationic amino acid transporter, y+ system), member 11 
(Slc7a11), the light chain subunit of system Xc- importing CySS and exporting 
glutamate, is the critical molecule for controlling extracellular Eh(Cys/CySS) 
(203). Lower Slc7a11 correlates with more oxidizing extracellular Eh(Cys/CySS) 
(203). The relationship between Slc7a11 and GSH/GSSH redox couple is less 
studied. Furthermore, Slc7a11 affects cysteine thiol oxidation status of 
intracellular proteins involved in pathways of protein turnover and cytoskeleton 
dynamics. These data suggest targeting Slc7a11 might be a candidate for 
interfering development of lung fibrosis. 
However, there is no study focusing on the role of redox couples and their 
redox potentials in IPF fibroblast pathology. Whether solute carrier family 7 
member 11 (SLC7A11) has similar regulatory effects on redox environments for 
human lung fibroblasts remains to be explored. The purpose of this study is to 
characterize extracellular and intracellular redox potentials for lung fibroblasts 
from IPF patients and non-IPF donors and to examine SLC7A11 expression 
and its relationship with redox couples in human fibroblasts. 
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4.2 Materials and methods 
4.2.1 Reagents 
Reagents used in this paper were all purchased from Sigma-Aldrich (St. 
Louis, MO) or Corning (Manassas, VA) unless otherwise specified. 
4.2.2 Fibroblast cultures from IPF patients and non-IPF donors 
Six lung specimens from explants of 6 IPF patients receiving lung 
transplantation in the University of Louisville Hospital were collected and used 
for IPF fibroblast isolation. All patients enrolled in this study provided written 
consent. This study was approved by University of Louisville Hospital Ethics 
Committee. Fresh tissues were transported immediately to the laboratory for 
isolating fibroblasts according to procedures described in Chapter 2 (176, 262). 
Non-IPF fibroblasts were kindly provided by Dr. Halayko. They were isolated 
from uninvolved periphery of 6 lung cancer patients. Those cancer-adjacent 
cells were used as controls. These human lung fibroblasts were cultured in 
Dulbecco's Modified Essential Medium (DMEM) with 10% fetal bovine serum 
(FBS) and 1% antibiotic-antimycotic mixture. Culture dishes were kept in a 
humidified incubator at 37 °C with 5% CO2. Fibroblasts with passage numbers 
before 10 were used in the experiments. Age and sex data of IPF patients and 
non-IPF donors are presented in Table 4.1. 
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Table 4.1 Age and sex of IPF patients and non-IPF donors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient number Age Sex 
IPF-1613 68 Male 
IPF-1705 65 Male 
IPF-1710 67 Male 
IPF-1713 71 Male 
IPF-1714 62 Female 
IPF-1715 64 Male 
Non-IPF-004 69 Female 
Non-IPF-005 64 Male 
Non-IPF-090 56 Female 
Non-IPF-103 80 Female 
Non-IPF-128 57 Female 
Non-IPF-138 55 Male 
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4.2.3 0 mV redox media preparation and fibroblast incubation 
DMEM without L-methionine, L-cystine and L-glutamine were used as the 
base media for preparation of 0 mV redox media. 0 mV media contained 0.2 
mM L-methionine, 4 mM L-glutamine, 99.75 μM L-cystine and 0.5 μM L-
cysteine. All 0 mV redox media were prepared immediately before media 
change. Fibroblasts were incubated with 0 mV redox media for 24 h. 
4.2.4 Derivatization of media and analysis of high-performance liquid 
chromatography (HPLC) 
Conditioned media were combined with the same amount of ice-cold 
solution composed of 200 mM boric acid, 10% (w/v) perchloric acid and 20 μM 
γ-glutamyl glutamate (177). Iodoacetic acid and dansyl chloride were used to 
derivatize the media for HPLC analysis (Waters Corporation, Millford, MA) (134, 
178). Calculations of Eh(Cys/CySS) and Eh(GSH/GSSG) are based on the 
Nernst equation for pH 7.4: Eh(Cys/CySS) = -250+30*log([CySS]/[Cys]2) and 
Eh(GSH/GSSG) = -264+30*log([GSSG]/[GSH]2) (203). 
4.2.5 Measurement of SLC7A11, COL1A1 and ACTA2 mRNA level 
RNAqueous®-4PCR Kit (Thermo Fisher Scientific, Waltham, MA) was used 
for isolating RNA from human lung fibroblasts of 5 IPF patients and 5 non-IPF 
donors without 0 mV redox media incubation. Non-IPF-103 and IPF-1714 were 
not included due to cell culture issues. SuperScript™ VILO™ Master Mix Kit 
(Thermo Fisher Scientific, Waltham, MA) was used to synthesize cDNA. Real-
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time quantitative PCR (qPCR) was conducted to measure SLC7A11, COL1A1, 
ACTA2 mRNA and eukaryotic 18S rRNA (18S) expression with TaqMan probes 
(TaqMan® Gene Expression Assay Hs00921938_m1, Hs00164004_m1, 
Hs00426835_g1 and Hs99999901_s1; Applied Biosystems), according to the 
manufacturer’s protocol (TaqMan Universal Master Mix II; Applied Biosystems). 
Step One Plus Real Time PCR System (Applied Biosystems) was used for 
qPCR. The following cycle parameters were used: 50°C for 2 min, 95°C for 
10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Results were 
analyzed using Step One Software version 2.3 (Applied Biosystems). The 
amplification curve was analyzed by the mathematical equation of the second 
derivative, and the amounts of SLC7A11, COL1A1, ACTA2 mRNA expression 
were normalized to the housekeeping gene 18S rRNA expression. Relative 
change compared to the average of non-IPF fibroblast samples were calculated 
for each cell isolate. Finally, relative expression of mRNA was calculated via 
using the 2-ΔΔCT method as in Chapter 2. 
4.2.6 Statistical analysis 
Data were presented as mean ± standard deviation. Significance was 
evaluated by unpaired two-tailed t-test. Linear regression was used to assess 
the correlation between redox potential and SLC7A11 expression. 
4.3 Results 
4.3.1 Extracellular Eh(Cys/CySS) for human lung fibroblasts 
Primary lung fibroblasts isolated from IPF patients produced more oxidized 
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extracellular Eh(Cys/CySS) than fibroblasts from non-IPF controls (Figure 
4.1.A). The average extracellular Eh(Cys/CySS) was -37mV for IPF fibroblasts 
and -70mV for non-IPF fibroblasts (Figure 4.1.A). Because Eh(Cys/CySS) was 
calculated from concentrations of Cys and CySS. I then looked at their 
individual concentrations. Data from 6 IPF and 6 non-IPF patients suggested 
that the average extracellular Cys concentration was 4 µM lower for IPF 
fibroblasts, accounting for this approximately 33 mV oxidation of Eh(Cys/CySS) 
(Figure 4.1.B). Such oxidation and the decrease in Cys were consistent with 
the previous mouse study that compared to young mice, extracellular 
Eh(Cys/CySS) was more oxidized for fibroblasts from aged mice whose 
susceptibility to lung fibrosis was also higher (157, 203). There was no 
difference of extracellular CySS concentration between IPF and non-IPF 
fibroblasts (Figure 4.1.C). 
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Figure 4.1 Extracellular Eh(Cys/CySS) became more oxidized for lung 
fibroblasts from IPF patients due to lower extracellular Cys concentration. Lung 
fibroblasts from uninvolved periphery of lung tissues of 6 lung cancer patients 
(non-IPF) and 6 IPF patients were isolated and cultured in DMEM containing 
10% fetal bovine serum. When the cultures were 50% confluent, media were 
replaced with serum-free media containing 100 µM CySS (0 mV redox media) 
for 24 hours. Media were collected to measure concentrations of Cys and CySS. 
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Extracellular Eh(Cys/CySS) was calculated using Nernst equation according to 
the following formula: Eh(Cys/CySS) = -250 + 30*log([CySS]/[Cys]2). (A) 
Extracellular Eh(Cys/CySS) was more oxidized for IPF fibroblasts. (B) 
Extracellular Cys concentration was lower for IPF fibroblasts. (C) Extracellular 
CySS concentration was not altered for IPF fibroblasts. *- Indicates p-value < 
0.05 compared to non-IPF fibroblasts. 
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4.3.2 Expressions of SLC7A11 and pro-fibrotic genes for human lung fibroblasts 
Consistent with the hypothesis, SLC7A11 expression was 13-fold lower in 
IPF fibroblasts, which could account for the oxidation of extracellular 
Eh(Cys/CySS) (Figure 4.2). Collagen type I (COL1A1), which is a typical 
extracellular matrix protein, and actin α-2, smooth muscle (ACTA2), which 
represents differentiation of fibroblasts into the more pro-fibrotic myofibroblasts, 
were shown to be higher in IPF fibroblasts (Figure 4.3).  
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Figure 4.2 SLC7A11 expression was lower for IPF fibroblasts. *- Indicates p-
value < 0.05 compared to non-IPF fibroblasts. 
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Figure 4.3 Expressions of pro-fibrotic genes were higher for IPF fibroblasts. (A) 
COL1A1 expression was higher for IPF fibroblasts. (B) ACTA2 expression was 
higher for IPF fibroblasts. *- Indicates p-value < 0.05 compared to non-IPF 
fibroblasts. 
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4.3.3 Intracellular Eh(GSH/GSSG) for human lung fibroblasts 
GSH/GSSG is the major intracellular redox couple. A further step was taken 
to investigate whether intracellular Eh(GSH/GSSG) was different between IPF 
and non-IPF fibroblasts. In contrast to extracellular Eh(Cys/CySS), intracellular 
Eh(GSH/GSSG) was not more oxidized in IPF fibroblasts (Figure 4.4). 
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Figure 4.4 Intracellular Eh(GSH/GSSG) was not more oxidized for IPF 
fibroblasts. After incubation with 0 mV redox media for 24 hours, cells were 
collected for measuring intracellular GSH and GSSG concentrations by HPLC. 
Intracellular Eh(GSH/GSSG) was calculated based on Nernst equation using 
the following formula: Eh(GSH/GSSG) = -264 + 30*log([GSSG]/[GSH]2). 
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4.4 Discussion 
The increase of a variety of biomarkers of oxidative stress has been 
observed in several IPF-derived samples (34, 60). Redox couples, Cys/CySS 
and GSH/GSSG, are among the most commonly used markers to indicate 
disruptions of redox homeostasis (75, 76, 80, 81). Plasma Eh(Cys/CySS) is 
around -80 mV for healthy elderly people (134). There is about 15 mV oxidation 
of plasma Eh(Cys/CySS) for the age-matched IPF patients according to 
unpublished data in our group. In the current study, the finding was extended 
that Eh(Cys/CySS) became more oxidized not only in human plasma, but also 
in media of human lung fibroblast cultures. Furthermore, decreased Slc7a11 
expression has been shown to be associated with more oxidized extracellular 
Eh(Cys/CySS) in mouse lung fibroblasts in Chapter 2. This correlation was also 
observed in human lung fibroblasts in this Chapter. IPF fibroblasts expressed 
lower SLC7A11 and their extracellular Eh(Cys/CySS) was more oxidized. 
Previous studies also showed media with oxidized Eh(Cys/CySS) increased 
pro-fibrotic gene expression in primary mouse lung fibroblasts (156). The pro-
fibrotic effect of oxidation of extracellular Eh(Cys/CySS) was confirmed in 
human fibroblasts in this chapter. Two representative fibrotic genes, COL1A1 
and ACTA2, were shown to be upregulated in IPF fibroblasts. In other words, 
SLC7A11-dependent reduction of extracellular Eh(Cys/CySS) in human 
fibroblasts was associated with lower pro-fibrotic gene expression, decreasing 
the susceptibility of fibrosis. Those data indicate that SLC7A11 might be a 
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potential anti-fibrotic target for intervening redox environments before IPF 
development and during IPF pathogenesis. Manipulating SLC7A11 might be 
effective in preventing and treating IPF. 
Regulation of intracellular Eh(GSH/GSSG) was independent of SLC7A11. 
Though SLC7A11 was lower in IPF fibroblast, intracellular Eh(GSH/GSSG) was 
not different between IPF and non-IPF fibroblasts. This is consistent with the 
finding that genetic manipulations of Slc7a11 in mouse lung fibroblasts had no 
effect on intracellular Eh(GSH/GSSG) in Chapter 2. It was not surprising that 
regulation of extracellular Eh(Cys/CySS) and intracellular Eh(GSH/GSSG) were 
mediated via different mechanisms. In fact, this is a good example to show 
oxidative stress was not simply overall imbalance between oxidants and anti-
oxidants but disruption of redox regulation network which contains components 
that are controlled independently of each other. 
The regulatory role of SLC7A11 on redox environments is dependent on 
the transporting activity of system Xc-. Exploration of why SLC7A11 was lower 
in IPF fibroblast and the relation between SLC7A11 expression and system Xc- 
activity is critical for understanding the pathogenesis of IPF. Studies of 
regulation of SLC7A11 expression and system Xc- activity are primarily focused 
on the transcription level and support the idea that transcriptional regulation of 
SLC7A11 is much more important for determining system Xc- activity compared 
to expression of SLC7A11-interacting heavy chain SLC3A2, which forms 
multiple transporting systems with different subunits and lacks specificity (263).  
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Transcriptional up-regulation of SLC7A11 has been shown to be mediated 
via 3 transcription factors, nuclear factor, erythroid 2 like 2 (NRF2), activating 
transcription factor 4 (ATF4) and ETS proto-oncogene 1, transcription factor 
(ETS-1) (264-266). NRF2 is a master switch for inducing expressions of 
multiple anti-oxidant genes. Not only SLC7A11, but also GSH metabolism-
associated genes, inducing glutamate-cysteine ligase (GCL), glutathione 
synthetase (GSS), glutathione S-transferase (GST), glutathione peroxidase 
(GPX), are all induced when NRF2 binds with the anti-oxidant response 
element (ARE) in the corresponding gene promoter in cell nuclei (267, 268). 
Without cellular stress, NRF2 is ubiquitinated via kelch like ECH associated 
protein 1/cullin 3/ring-box 1 (KEAP1/CUL3/RBX1) E3-ubiquitin ligase complex 
and degraded via proteasome (269). ROS, electrophiles and heavy metals 
have been shown to up-regulate SLC7A11 via disrupting the inhibitory effect of 
KEAP1 on NRF2 and promoting translocation of NRF2 into the nuclei (270, 
271). ATF4 mediates SLC7A11 induction via nutrient deficiency (272). Amino 
acid deprivation, such as CySS starvation, results in increased number of 
unloaded t-RNAs (273). Free t-RNAs then activates general control non-
derepressible 2 (GCN2), which is a kinase that phosphorylates eukaryotic 
translation initiation factor 2α (eIF2α) (274). Phosphorylation of eIF2α further 
promotes translation of ATF4, and ATF4 promotes SLC7A11 transcription via 
binding to the amino acid response element (AARE) in SLC7A11 promoter 
region (275). Furthermore, ETS proto-oncogene 1, transcription factor (ETS-1), 
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downstream of RAS, increases SLC7A11 expression in synergy with ATF4, 
suggesting the supportive role of SLC7A11 in RAS-induced tumorigenesis 
(266). 
Other transcription factors can down-regulate SLC7A11 transcription, 
including p53, ATF3, BTB and CNC homology 1 (BACH1) and POU class 2 
homeobox 1 (POU2F1) (276-279). The p53 protein is a famous tumor 
suppressor that regulates genes associated with cell cycle arrest, apoptosis 
and senescence (280). Though p53 inhibits SLC7A11 transcription, mutation of 
p53 does not always accompany over-expression of SLC7A11 in multiple 
tumors, further supporting the idea that transcription of SLC7A11 is regulated 
by multiple mechanisms (249, 276, 281). SLC7A11 is closely associated with 
ferroptosis, a non-apoptotic and iron-dependent form of regulated cell death 
resulted from GSH exhaustion and lipid peroxides accumulation (282). ATF3, 
which is induced by various cellular stresses including DNA damage and 
oxidative stress, decreases SLC7A11 transcription in a p53-independent way 
and promotes erastin-induced ferroptosis (277, 283, 284). BACH1 competes 
with NRF2 for ARE in promoters of redox associated genes (285). Contrary to 
NRF2, BACH1 suppresses expressions of those anti-oxidant genes including 
SLC7A11, stimulating ferroptosis (279, 286). POU2F1 also binds with SLC7A11 
promoter region and inhibits SLC7A11 transcription, resulting in change of 
melanin production of melanocytes and change of fur color in rabbits (278). 
Deubiquitinases involved in chromatin modification have been shown to 
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inhibit SLC7A11 transcription. BRCA1-associated protein 1 (BAP1) is a tumor 
suppressor and inhibits SLC7A11 expression via decreasing H2A ubiquitination 
(287, 288). Under ferroptotic stress, p53 binds with ubiquitin-specific peptidase 
7 (USP7) and promotes USP7 translocation into the nuclei, where USP7 
inactivates SLC7A11 transcription via removing monoubiquitination of histone 
H2B at lysine 120 (H2Bub1) (289). This inhibitory effect of p53 on SLC7A11 
expression via epigenetic chromatin regulation is independent of its inhibitory 
effect as a transcription factor (289). 
Chromatin remodeling molecules also influence SLC7A11 transcription. 
SWI/SNF chromatin-remodeling complex is altered in many cancers (290). AT-
rich interaction domain 1A (ARID1A) gene encodes one component of this 
complex (291). It enhances the effect of NRF2 on inducing SLC7A11 (292). 
ARID1A deficiency impairs NRF2 recruitment and NRF-mediated SLC7A11 
transcription (292). However, over-expression of NRF2 rescues SLC7A11 
expression, indicating ARID1A is not essential for SLC7A11 induction (292). 
MicroRNAs (miRNAs) bind with and suppress SLC7A11 mRNA. MiR-26b, 
miR-27a, miR‑126‑3p, miR‑126‑5p, miR-372, miR-373, miR-374b-5p, miR-375, 
miR-627-5p, miR-3683, miR-4669 and miR-4740-3p have all been shown to 
target 3’-untranslated region (3’-UTR) of SLC7A11 transcripts to inhibit 
SLC7A11 mRNA translation or to promote SLC7A11 mRNA degradation (293-
301).  
A variety of endogenous cytokines and exogenous stimulants, such as 
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interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), fibroblasts growth factor 
2 (FGF2), erythropoietin (EPO) and bacterial lipopolysaccharide (LPS), 
increases SLC7A11 transcription (195). However, the mechanisms are not 
elucidated. 
Interactions between SLC7A11 protein and other molecules can increase 
or decrease the activity of system Xc-., depending on the interactive molecules. 
EGFR physically interacts with and stabilizes SLC7A11 protein in a kinase-
independent manner in EGFR-expressing glioma cells, which manifest 
increased CySS uptake and enhanced anti-oxidant capacity (250). CD44 is an 
adhesion molecule (302). Variant isoform of CD44 (CD44v) is expressed in 
epithelial tumors (303). CD44v interacts with and stabilizes SLC7A11, 
maintaining higher intracellular GSH synthesis for survival of gastrointestinal 
cancer cells (304). CD44v-SLC7A11 interaction is also involved in acquisition 
of cisplatin-resistance in lung cancer and 5-fluorouracil-resistance in gastric 
cancer (305, 306). CD133, a cancer stem cell marker, is shown to stabilize 
SLC7A11 and increase survival and drug resistance of liver cancer cells (307). 
The stability of SLC7A11 also requires the heavy chain SLC3A2 (308). On the 
contrary, formation of SLC7A11-Beclin 1 (BECN1) complex inhibits system Xc- 
activity (309, 310). BECN1 is a key component in the stage of nucleation during 
autophagy (311). Sulfasalazine and erastin induce phosphorylation and 
activation of AMP-activated protein kinase (AMPK) (309). AMPK further 
phosphorylates BECN1 (309). Phosphorylated BECN1 interacts with SLC7A11 
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protein directly, resulting in suppression of system Xc- activity (309). Inhibition 
of system Xc- activity via formation of BECN1-SLC7A11 complex has also been 
shown to mediate isoflurane-induced toxicity (310). 
Post-translational modifications of SLC7A11 also change the activity of 
system Xc-. OTU deubiquitinase, ubiquitin aldehyde binding 1 (OTUB1) directly 
interacts with SLC7A11 and stabilizes SLC7A11 via deuibiquitination (312). 
Furthermore, this OTUB1-SLC7A11 interaction is enhanced via overexpression 
of CD44 (312). On the contrary, mTORC2 interacts with and phosphorylates 
SLC7A11, resulting in inhibition of system Xc- activity (313). 
Methylation of SLC7A11 DNA is shown to be inversely correlated with 
alcohol consumption in a study using saliva samples from European American 
males and another study using blood samples from non-Hispanic white females 
(314, 315). 
Whether expression and stability of SLC7A11 are regulated via these or 
other mechanisms and how activity of system Xc- change correspondingly 
remain to be explored in IPF and non-IPF human fibroblasts. 
In conclusion, lung fibroblasts from IPF patients have more oxidized 
extracellular Eh(Cys/CySS) than lung fibroblasts from non-IPF donors. Lower 
SLC7A11 could account for the oxidation of extracellular Eh(Cys/CySS) and 
subsequent increase of pro-fibrotic genes in IPF fibroblasts. Future studies will 
explore how SLC7A11 is dysregulated in IPF fibroblasts to identify new 
therapeutic targets for preventing and reversing lung fibrosis.
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CHAPTER V 
 
SUMMARY AND DISCUSSION 
 
5.1 Slc7a11 and its role in regulating redox environments for lung fibroblasts 
Because of the earlier emergence of oxidation of redox potentials 
compared to clinical symptoms and the pro-fibrotic effects of such oxidation, it 
is imperative to explore how redox potential is regulated and whether oxidation 
could be intervened and reversed. Previous studies have shown Slc7a11 is a 
candidate for controlling redox potentials. 
Aging is associated with oxidation of redox potentials. Plasma 
Eh(Cys/CySS) becomes progressively oxidized at a linear rate of 0.16 mV/year 
over the entire age span (136, 137). Plasma Eh(GSH/GSSG) is stable before 
45 years old, but gets oxidized at a faster rate of 0.7 mV/year after 45 years old 
(136, 137). Lung fibroblasts isolated from old mice produce a more oxidizing 
extracellular Eh(Cys/CySS) than fibroblasts from young mice, which reproduces 
age-dependent oxidation of redox environment observed in human plasma 
(157). Furthermore, the capacity to recover from oxidative challenge is 
decreased in old fibroblasts as it takes longer time to re-establish the set-point 
value of extracellular Eh(Cys/CySS) for those old fibroblasts (157). Therefore, 
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those primary lung fibroblasts from young and old mice provide us with a good 
in vitro model to explore the regulation of redox potentials. 
Concomitant with oxidation of extracellular Eh(Cys/CySS), the expression 
of Slc7a11 is 10-fold lower in old fibroblasts than young fibroblasts (157). 
Slc7a11 is the substrate-specific part of system Xc-, a CySS/glutamate 
antiporter located on cell membrane (172, 316). System Xc- is a heterodimer 
and composed of the light chain Slc7a11 and the heavy chain Slc3a2 (317). 
The ratio of system Xc--mediated CySS import and glutamate export is 1:1 (318). 
Slc7a11 determines the specific function and activity of system Xc- (195, 319). 
Slc3a2 is also known as CD98 or 4F2 heavy chain and is responsible for 
trafficking of Slc7a11 to the cell membrane as a chaperone (320, 321). Slc3a2 
also interacts with other light chains to form other amino acid transporters (322-
324). Therefore, Slc7a11 plays a more important role in studying regulation of 
system Xc- activity. 
Slc7a11 connects the Cys/CySS and GSH/GSSG redox couples (Figure 
5.1). After CySS is imported via Slc7a11, it is reduced rapidly to Cys 
enzymatically by thioredoxin reductase 1 (Txnrd1) or thioredoxin domain 
containing 17 (Txndc17) or non-enzymatically by GSH because of the much 
more reducing intracellular environment compared to the extracellular 
environment (186, 195). Cys produced from Slc7a11-mediated CySS import is 
the major source of cellular Cys, although in several tissues, Cys can be 
synthesized from homocysteine or methionine via transsulfuration pathway 
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(325, 326). Cys can be exported by system ASC directly and oxidized back to 
CySS (327). Cys is also the rate limiting component for intracellular GSH 
synthesis (188). Glutamate-cysteine ligase (GCL) catalyzes the combination of 
Cys and glutamate to form γ-glutamyl cysteine, and glutathione synthetase 
(GSS) further catalyzes the addition of glycine to γ-glutamyl cysteine to 
generate GSH (175). GSH is the major small molecular anti-oxidant inside the 
cells. It reduces various oxidants with or without enzymes, mitigating oxidative 
stress. GSSG is the oxidative product formed from two molecules of GSH linked 
by a disulfide. GSSG can be reduced back to GSH by glutathione reductase 
with electrons from NADPH (328). Both GSH and GSSG can be exported by 
the multi-drug resistance protein (MRP) (329-331). Outside of the cells, 
membrane-bound γ-glutamyl transferase (GGT) breaks down GSH to release 
glutamate and cysteinyl glycine (332). Dipeptidase then cleaves cysteinyl 
glycine to produce Cys and glycine (332). Though other transporters are 
present, Slc7a11-dependent transporting system Xc- is pivotal for the 
maintenance of the cycle between Cys/CySS and GSH/GSSG. 
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Figure 5.1 Connection between Cys/CySS and GSH/GSSG redox couples. 
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The biological roles of Slc7a11 are based on system Xc--mediated CySS 
import and could be mediated by system Xc--related Cys release. It has been 
observed that age-dependent oxidation of extracellular Eh(Cys/CySS) 
coincides with age-dependent decrease of Slc7a11 in primary lung fibroblasts, 
suggesting the potential regulatory role of Slc7a11 on redox potentials (157). 
Chapter 2 shows Slc7a11 is the key controller of extracellular Eh(Cys/CySS) 
(203). Furthermore, induction or over-expression of Slc7a11 correlates with 
increase of extracellular Cys concentration, while suppression or knock-down 
of Slc7a11 correlates with decrease of extracellular Cys concentration (203). 
Extracellular CySS concentration does not change significantly after Slc7a11 
manipulation (203). Those results show although Slc7a11 imports CySS directly, 
it is the exported Cys that mediates the regulatory effect of Slc7a11 on 
extracellular Eh(Cys/CySS). Blocking intracellular GSH synthesis results in 
dramatic depletion of extracellular GSH concentration without affecting 
extracellular Cys concentration, indicating GSH synthesis and export might not 
be essential for regulation of extracellular Eh(Cys/CySS) (203). In support of my 
observations, another study also shows that system Xc--mediated CySS uptake 
drives Cys release in both vascular smooth muscle cells and endothelial cells 
(333). Rather than the increased intracellular GSH, the reducing extracellular 
environment created by system Xc--associated Cys release increases 
lymphoma cell survival (190). Change of extracellular Eh(Cys/CySS) itself also 
has multiple biological influences, which has been discussed in previous 
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paragraphs in Section 1.3. Taken together, one possible mechanism by which 
Slc7a11 exerts its functions could be directly linked to regulation of Cys/CySS 
balance and its redox potential without requiring the interaction between 
Cys/CySS and GSH/GSSG redox couples. 
Slc7a11 regulates intracellular redox environments in a GSH-dependent 
manner, and the effects can also be reflected by multiple peptidyl cysteines. 
Cysteines are widely distributed among proteins and could be important sites 
for post-translational modifications (334, 335). Cys can be in the reduced form 
or a variety of oxidized forms (336). Some of the oxidize forms are reversible 
(e.g. disulfide, sulfinic acid) while some are not (e.g. sulfonic acid) (163). Some 
thiols exist in the active thiolate form with negative charge while some are not 
based on local pH (208). Cys can also form coordination compounds with 
transition metal ions (337). The structural diversity of Cys results in the 
functional flexibility. Redox state of a specific peptidyl Cys is quantitatively 
represented by the ratio of the oxidized portion to the reduced portion of this 
Cys. The results in Chapter 3 show redox states of Cys change spontaneously 
with aging. Though oxidative stress increases with aging, redox states do not 
become oxidized for all Cys residues, indicating that in addition to the general 
oxidation of intracellular redox environment, specific pathways are regulated 
individually via redox regulation. Slc7a11 decreases aging (157, 203). 
Considering Cys reduced from system Xc--imported CySS provides the rate-
limiting component for GSH synthesis, decrease of Slc7a11 level could result 
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in decrease of intracellular GSH level, disrupting the balance of intracellular 
redox environments and redox signaling. Many studies have confirmed 
decrease or Slc7a11 expression or inhibition of system Xc- activity results in 
decrease of GSH, rendering cells more susceptible to death (338-340). 
However, the downstream effects on redox states of Cys and redox signaling 
are less studied. My studies fill the gap and indicate that over-expression of 
Slc7a11 might compensate for its age-dependent deficiency and re-establish 
the optimal homeostasis of redox environments. Furthermore, restoration of 
intracellular redox environment further results in reverse of Cys redox states 
and redox signaling, at least partially. In Chapter 3, I have found the most 
affected age-dependent Slc7a11-responsive signaling pathways are eukaryotic 
translation initiation factor 2 (EIF2) signaling, actin cytoskeleton and integrin-
linked kinase (ILK) signaling and protein ubiquitination pathway. These 3 
pathways demonstrate that peptidyl Cys residues whose redox states change 
with aging but are reversible by Slc7a11 over-expression are enriched in basic 
biological activities including protein turnover and cytoskeleton dynamics. 
Mechanisms responsible for regulating redox environments are altered 
during IPF pathogenesis. Chapter 4 shows human lung fibroblasts from IPF 
patients produce a more oxidizing extracellular Eh(Cys/CySS) than fibroblasts 
from non-IPF donors. This is consistent with my observation that plasma 
Eh(Cys/CySS) of IPF patients is more oxidized than that of non-IPF donors. 
Considering Slc7a11 is the key regulator of extracellular Eh(Cys/CySS) in 
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primary mouse lung fibroblasts, I hypothesize Slc7a11 could have similar roles 
in human lung fibroblasts. However, higher Slc7a11 expression only correlates 
with more reduced extracellular Eh(Cys/CySS) in non-IPF fibroblasts, while this 
correlation is impaired in IPF fibroblasts. Furthermore, the correlation between 
Slc7a11 expression and intracellular Eh(GSH/GSSG) in non-IPF fibroblasts is 
also disrupted in IPF fibroblasts. Those results indicate Slc7a11 might lose its 
role of mediating the cycle between Cys/CySS and GSH/GSSG redox couples 
during IPF development. 
5.2 Strengths and weaknesses  
Studies in this dissertation focus on regulation of both extracellular and 
intracellular redox environments by fibroblasts. The interaction between 
fibroblasts and redox environments are comparable to that between fibroblasts 
and matrix proteins. Oxidation of extracellular environments stimulates pro-
fibrotic responses of fibroblasts while fibroblasts are able to regulate their redox 
environments. However, the regulatory capability was impaired with aging, the 
most important risk factor of IPF, and altered during IPF fibrogenesis. Change 
of redox environments could occur even before the appearance of irreversible 
fibrosis, indicating potential clinical significance for early intervention to halt or 
even reverse fibrosis. My model of lung fibroblasts from young and old mice 
simulates the effects of aging in vitro and allows us to explore why the ability of 
maintaining optimal redox environments is decreased with aging and what is 
the key controller of redox environments for fibroblasts. The young and old 
119 
fibroblasts were isolated from healthy mice. The studies in this dissertation tried 
to uncover how the susceptibility increases before the actual fibrosis happens. 
Thus, it is the initial step towards finding novel targets for early intervention to 
decrease IPF susceptibility. This dissertation also begins to examine whether 
mouse and human fibroblasts share similar regulatory mechanisms of redox 
environments and compare IPF and non-IPF fibroblasts. This is the further step 
towards revealing whether actual redox environments and their regulatory 
mechanisms are altered in the diseased status of IPF. This is the foundation of 
developing targets for future clinical trials. 
There are several limitations. First, fibroblasts are not the only cells involved 
in IPF pathogenesis. Epithelial cells, inflammatory cells, endothelial cells and 
pericytes might all have different and complementary roles to play. Their exact 
contributions to IPF are not fully elucidated. Whether and how those cell types 
contribute to regulation of redox environments and whether there are 
interactions between fibroblasts and other cell types remain unexplored. 
Second, the discrepancies of redox regulation mechanism between IPF and 
non-IPF fibroblasts could be attributed to the small sample size. Fibroblasts 
from only 6 IPF patients and 6 non-IPF donors are available. It is unknown 
whether adding more samples will change the conclusion. Last, confirmation of 
the changes of redox states of peptidyl cysteines in the age-dependent 
Slc7a11-responsive pathways are needed as redox proteomic assays are not 
as accurate as individual experiments targeting specific proteins. 
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5.3 Future directions 
5.3.1 What is the role of Slc7a11 in mediating the anti-fibrotic effects of 
sulforaphane in bleomycin-induced lung fibrosis mouse model? 
This dissertation focuses on exploring the role of Slc7a11 in regulating 
extracellular and intracellular redox environments mouse and human lung 
fibroblasts in vitro. In vivo experiments using wild-type and Slc7a11 knock-out 
mice will further clarify the role of Slc7a11. Sulforaphane is used in Chapter 2 
to induce Slc7a11 expression. Sulforaphane has also been shown to decrease 
mRNA expression of pro-fibrotic genes and deposition of collagen, mitigating 
bleomycin-induced lung fibrosis in mice (341). It will be interesting to explore 
whether Slc7a11 mediates these anti-fibrotic effects of sulforaphane. 
5.3.2 How expression of Slc7a11 is regulated with chronological aging? 
Chapter 2 shows Slc7a11 expression is lower in fibroblasts isolated from 
old mice compared to young mice. Why aging results in decrease of Slc7a11 
remains to be explored. Chapter 4 includes summaries of transcriptional and 
post-transcriptional regulation of Slc7a11 expression and post-translational 
regulation of Slc7a11 activity. Whether those mechanisms are responsible for 
the age-dependent decrease of Slc7a11 in primary mouse lung fibroblasts and 
whether there are other mechanisms involved remain to be explored. 
5.3.3 Is there a connection between cellular senescence and Slc7a11 
expression? How do they relate to each other? 
Fibroblasts isolated from IPF patients display multiple characteristics of 
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cellular senescence (29). Chapter 3 shows Slc7a11 restores age-dependent 
changes of redox potentials of many proteins. It will be interesting to explore 
whether Slc7a11 manipulations could reverse changes of senescent markers. 
If Slc7a11 could indeed affect the process of aging, it will be of great value to 
study how such effect is connected to the susceptibility of IPF.
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LIST OF ABBREVIATIONS 
α-SMA Alpha-smooth muscle actin 
AARE Amino acid response element 
ACTA2 Actin α-2, smooth muscle 
AD Alzheimer disease 
AEC Alveolar epithelial cell 
Akt2 Serine/threonine kinase 2 
AMPK AMP-activated protein kinase 
ARE Anti-oxidant response element 
ARID1A AT-rich interaction domain 1A 
ATF4 Activating transcription factor 4 
BACH1 BTB and CNC homology 1 
BAL Bronchoalveolar lavage 
BAP1 BRCA1-associated protein 1 
BECN1 Beclin 1 
BP Biological process 
BSO Buthionine sulfoximine 
CAT Catalase 
CC Cellular component 
CD44 Cluster of differentiation 44 
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CD44v Variant isoform of CD44 
CO2 Carbon dioxide 
COL1A1 Collagen type I 
COPD Chronic obstructive pulmonary disease 
CREB cAMP response element binding protein 
CRMP-2 Collapsin response mediator protein-2 
CUL3 Cullin 3 
Cys Cysteine 
CySS Cystine 
DAVID Database for Annotation, Visualization and Integrated 
Discovery 
DMEM Dulbecco's Modified Essential Medium 
EBC Exhaled breath condensate 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
Eh Redox potential 
EIF2 Eukaryotic translation initiation factor 2 
eIF2α Eukaryotic translation initiation factor 2α 
EIF4E Eukaryotic translation initiation factor 4E 
ELF Epithelial lining fluid 
EMT Epithelial-to-mesenchymal transition 
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EPO Erythropoietin 
ERK Extracellular signal-regulated kinase 
ETS-1 ETS proto-oncogene 1, transcription factor 
FBS Fetal bovine serum 
FDR False discovery rate 
FGF2 Fibroblasts growth factor 2 
FLNB Filamin B 
GCL Glutamate-cysteine ligase 
GCLC Catalytic subunit of glutamate-cysteine ligase 
GCLM Modifier subunit of glutamate-cysteine ligase 
GCN2 General control non-derepressible 2 
GGT Gamma-glutamyl transferase 
GO Gene Ontology 
GPX Glutathione peroxidase 
GRX Glutaredoxin 
GSH Glutathione 
GSS Glutathione synthetase 
GSSG Glutathione disulfide 
GST Glutathione S-transferase 
H2O Water 
H2O2 Hydrogen peroxide 
HIV Human immunodeficiency virus 
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HPLC High-performance liquid chromatography 
HRCT High-resolution computed tomography 
HSP70 Heat shock protein 70 
ICAT Isotope-coded affinity tag 
IL-1β Interleukin-1β 
ILK Integrin-linked kinase 
iNOS Inducible nitric oxide synthase 
IodoTMT Iodoacetyl tandem mass tag 
IPA Ingenuity Pathway Analysis 
IPF Idiopathic pulmonary fibrosis 
KEAP1 Kelch like ECH associated protein 1 
KEGG Kyoto Encyclopedia of Genes and Genomes  
LAP Latency-associated protein 
LC-MS/MS Liquid chromatography-tandem mass spectrometry 
LPS Lipopolysaccharide 
LTBP Latent TGF-β binding protein 
MAPK Mitogen-activated protein kinase 
MDA Malondialdehyde 
MF Molecular function 
mGlu5 Metabotropic glutamate receptor 5 
miRNA MicroRNA 
MMP Matrix metallopeptidase 
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MRP Multi-drug resistance protein 
mTORC1 Mammalian target of rapamycin complex 1 
NAC N-acetylcysteine 
NADH Reduced nicotinamide adenine dinucleotide 
NADPH Reduced nicotinamide adenine dinucleotide phosphate 
NF-κB Nuclear factor-κB 
NOX NADPH oxidase 
NRF2 Nuclear factor, erythroid 2 like 2 
O2 Oxygen 
O2- Superoxide anion 
OTUB1 OTU deubiquitinase, ubiquitin aldehyde binding 1 
PBS Phosphate-buffered saline 
PCA Perchloric acid 
Pin 1 Peptidyl-prolyl cis-trans isomerase 1 
POU2F1 POU class 2 homeobox 1 
PPI Protein-protein interaction 
PPP2CA Protein phosphatase 2 catalytic subunit alpha 
PRX Peroxiredoxin 
qPCR Quantitative PCR 
RBX1 Ring-box 1 
Redox Reduction and oxidation 
ROH Alcohol 
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ROOH Organic hydroperoxide 
ROS Reactive oxygen species 
RPL9 Ribosomal protein L9 
RPS6 Ribosomal protein S6 
SAMP8 Senescence-accelerated mouse-prone 8 
SASP Senescence-associated secretory phenotype 
SDS Sodium dodecyl sulfate 
Slc7a11 Solute carrier family 7, member 11 
SOD Superoxide dismutase 
SRX Sulfiredoxin 
System ASC System alanine-serine-cysteine 
TBS Tris-buffered saline 
TCA Trichloroacetic acid 
TCEP Tris(2-carboxyethyl)phosphine 
TEAC Trolox equivalent anti-oxidant capacity 
TGF-β Transforming growth factor-β 
TLN1 Talin 1 
TNFα Tumor necrosis factor α 
TRX Thioredoxin 
Txndc17 Thioredoxin domain containing 17 
Txnrd1 Thioredoxin reductase 1 
UCHL-1 Ubiquitin carboxyl terminal hydrolase L-1 
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UIP Usual interstitial pneumonia 
USP7 Ubiquitin-specific peptidase 7 
3’-UTR 3’-untranslated region 
4F2hc 4F2 heavy chain 
8-OHdG 8-hydroxy-deoxyguanosine 
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